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Welcome and Introductions 
Dr. Jonathan Temte
ACIP Chair
Dr. Larry Pickering 
Executive Secretary, ACIP / CDC
Following Dr. Temte’s greeting and call to order, Dr. Pickering welcomed everyone to the
February 2015 Advisory Committee on Immunization Practices (ACIP) meeting.  He expressed
appreciation for everyone’s understanding about the CDC closure and the necessary
cancellation of the first day of the meeting due to the inclement weather. He indicated that the
proceedings of this meeting would be available to people not in attendance via the World Wide
Web, and welcomed those who could not attend the meeting in person.  He then recognized 
Stephanie Thomas and Natalie Greene who were to be present throughout the duration of the
meeting to assist with various meeting functions.
Emphasizing that there would be a crowded agenda for the day, Dr. Pickering noted that
handouts of presentations were distributed to the ACIP members and were made available for
others on the tables outside of the auditorium.  Slides presented during this meeting will be 
posted on the ACIP website approximately two weeks after the meeting concludes, the live 
webcast will be posted within four weeks following the meeting, and the meeting minutes will be 
available on the website within 90 days following this meeting.  Meeting minutes are posted on 
the ACIP website generally within 90 days of ACIP meetings.  Members of the press interested
in conducting interviews with ACIP members were instructed to contact Michael Sennett, Joey
Smith, or KD Hoskins for assistance in arranging interviews.
Dr. Pickering welcomed the following international guests in attendance:
 Nearly every meeting, a delegation attends from a member country of the World Health
Organization’s (WHO’s) Pan-American Health Organization (PAHO).  Members of Peru’s
National Immunization Technical Advisory Group (NITAG) attended this meeting, led by Dr.
Robert Espinozo, NITAG Chair. With Dr. Espinozo were Dr. Washington Toledo, National
Immunization Program Manager; and Dr. Abel Salinas and Ms. Lourdes Castillo, NITAG
members.
 Seven members of India’s National Technical Advisory Group on Immunization (NTAGI), led 
by Dr. Gangadeep Kang; and three members of the NTAGI secretariat, led by Dr. Inamdar
were present.  Dr. Kang is a Professor in the Department of Gastrointestinal Sciences at the
Christian Medical College in Vellore, India and is a member of India’s NTAGI.  Dr. Inamdar
is the Senior Advisor for Evidence to Policy at the Immunization Technical Support Unit
(ITSU) in the Public Health Foundation of India (PHFI), and is a member of the NTAGI
Secretariat.
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 The following three long-time friends were in attendance from Japan:
 Dr. Mitsuaki Hosoya, Chair and Professor of Pediatrics at Fukushima Medical
University in Fukushima, Japan
 Dr. Nobuhiko Okabe, Director General of Kawasaki City Institute for Public Health in 
Japan.
 Dr. Hajime Kamiya, Medical Officer, National Institutes of Infectious Diseases in 
Tokyo, Japan.
.
Notes regarding members and liaison representatives included the following:
Ex Officio Members
 Jeff McCollum attended this meeting on behalf of Amy Groom, representing the Indian 
Health Service (IHS).
 Dr. Eric Sergienko is the new ex officio member representing the Department of Defense 
(DoD).
Liaisons 
 Dr. Caroline Quach attended on behalf of Dr. Ian Gemmill, representing the Canadian 
National Advisory Committee on Immunization (NACI).
 Dr. Kimberly Martin attended on behalf of Dr. Terry Dwelle, representing the Association of
State and Territorial Health Officials (ASTHO).
 ACIP welcomed the American College of Nurse Midwives (ACNM) as a new liaison 
organization, and Carol Hayes as their representative.  ACNM is one of four professional
organizations that works with CDC in preparation of the yearly adult immunization schedule.
 Dr. Carrie Byington, representative of the American Academy of Pediatrics (AAP) was
appointed Chair of AAP’s Committee on Infectious Diseases (COID) on July 1, 2014.
 Dr. Ken Schmader, American Geriatric Society (AGS), attended via teleconference.
To avoid disruptions during the meeting, Dr. Pickering requested that those present turn off all
cell phones.  He explained that topics presented during the ACIP meeting include open 
discussion with time reserved for public comment.  During this meeting, a time for public
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comment was scheduled following the afternoon sessions during both meeting days. Time for
public comments also may be provided prior to specific votes by ACIP to enable these
comments to be considered before any votes. Those who planned to make public comments
were instructed to visit the registration desk in the rear of the auditorium to have Stephanie 
Thomas record their name and provide information about the process. Those who registered to 
make public comments were instructed to state their name, organization if applicable, and any
conflicts of interest (COIs) prior to making their comments.
Safety issues will continue to be presented during every ACIP meeting.  During this meeting,
these issues were included as part of specific topic presentations.
With regard to disclosure, to summarize conflict of interest provisions applicable to ACIP, as
noted in the ACIP Policies and Procedures manual, Dr. Pickering indicated that members of the
ACIP agree to forego participation in certain activities related to vaccines during their tenure on 
the committee.  For certain other interests that potentially enhance a member’s expertise while 
serving on the committee, CDC has issued limited conflict of interest waivers.  Members who 
conduct vaccine clinical trials or who serve on data safety monitoring boards (DSMBs) may
present to the committee on matters related to those specific vaccines.  However, they are
prohibited from participating in committee votes on issues related to those specific vaccines.
Regarding other vaccines of the affected company, a member may participate in a discussion 
with a proviso that he or she abstains on all votes related to the vaccines of that company. It is
important to note that at each meeting, ACIP members state any conflicts of interest.
Applications for ACIP membership are due no later than November 13, 2015 for the 4-year term
beginning July 2016. Detailed instructions for submission of names of potential candidates to
serve as ACIP members may be found on the ACIP web site:
E-mail: acip@cdc.gov Web homepage: http://www.cdc.gov/vaccines/acip/index.html
Nominations: http://www.cdc.gov/vaccines/acip/committee/req-nominate.html
A current CV, at least one recommendation letter from a non-federal government employee, and
complete contact information are required. These may be submitted as e-mail attachments to 
Stephanie Thomas at hkp4@cdc.gov
During every ACIP meeting, an update is provided with regard to the status of ACIP
recommendations. There have been two publications since October 2014: the Child 
Adolescent Immunization Schedule and the Adult Immunization Schedule.  In addition, “ACIP
Recommendations on the Use of Typhoid Vaccines” are projected to be published in the 
MMWR on March 27, 2015.
Recommendations and immunization schedules can be downloaded from the ACIP website.
ACIP has a policy that every three to five years, each recommendation is reviewed and then 
renewed, revised, or retired.
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Immunization for Women (American College of Obstetricians and Gynecologists):
www.immunizationforwomen.org
You Are the Key to HPV Cancer Prevention:
http://www.cdc.gov/vaccines/youarethekey
Vaccines for Preteens and Teens:
http://www.cdc.gov/vaccines/who/teens/index.html
Before officially beginning the meeting, Dr. Temte called the roll to determine whether any ACIP
members had conflicts of interest. The following conflicts of interest were declared:
 Belongia: Receives research funding from MedImmune and has a conflict on influenza
vaccines
 Bennett, Bocchini, Campos-Outcalt, Harrison, Harriman, Karron, Kempe, Pellegrini,
Reingold, Riley, Romero, Rubin, Temte, and Vazquez:  No conflicts
Dr. Temte then acknowledged Dr. Pickering’s many years of service.  He said that he had the 
pleasure of first meeting Dr. Pickering when they were both involved in the March 2000 CDC 
Measles Elimination Meeting convened in Atlanta. Over those years, he noticed the number of
people who were in attendance at that meeting who have also been present at ACIP meetings.
Dr. Temte noted that they also had the great pleasure of having Dr. Pickering’s wife, Mimi, and 
daughter, Maggie, in attendance during this meeting.  His son, Andrew, was unable to attend
due to a scheduling conflict.  Dr. Temte recounted that everyone sitting around the table had
benefitted from the hospitality of the Pickerings, who have often hosted some of the ACIP
members for a respite and wonderful home-cooked meal.
As the Executive Secretary of ACIP, Dr. Pickering has overseen more than 25 ACIP meetings.
He has brought uniformity in presentations and enhanced the level of all of the work being done
by the committee, including high quality products.  He has conducted meetings through 
outbreaks, a pandemic, a government shutdown, and now during a Southern snowstorm.  He
has shepherded over 50 ACIP-related MMWR articles, including articles on universal influenza 
vaccination and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap)
administration during pregnancy.  He was instrumental in the adoption of the Grading of
Recommendation Assessment, Development and Evaluation (GRADE) Methodology in 2010;
has been an eloquent spokesperson for vaccines and CDC’s immunization policies and 
recommendations; and has graced everyone with his expertise, experience level, sensibilities,
sensitivities, wisdom, and leadership over the last 9 years.
10 
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In conclusion, Dr. Temte said, “It’s a magical world, Larry ol’ buddy. We just want to give you 





Chair, Meningococcal Work Group
Advisory Committee on Immunization Practices
Dr. Rubin expressed his gratitude to Dr. Pickering for all of his contributions.  He indicated that
in the interest of time, this session would include a discussion of and vote on the meningococcal
B vaccine for high-risk individuals.  Discussion of the broader use of meningitis B vaccines for
adolescents will be deferred until the June 2015 meeting.
Considerations for use of Serogroup B Meningococcal
(MenB) Vaccines in Persons at Increased Risk
Jessica MacNeil, MPH
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
For use of serogroup B meningococcal (MenB) vaccines in persons at increased risk, Ms.
MacNeil summarized current meningococcal vaccination recommendations for persons at
increased risk, reviewed the groups at increased risk for serogroup B meningococcal disease,
reviewed immunogenicity and safety data for the MenB vaccines, summarized the outcomes
from the GRADE evaluation, and presented proposed policy option language for a vote.
Meningococcal conjugate vaccines are routinely recommended for persons ≥2 months of age at
increased risk for meningococcal disease, including persons with persistent complement
component deficiencies, persons with anatomic or functional asplenia, microbiologists who are
exposed routinely to isolates of Neisseria meningitidis, persons at risk during a community
outbreak attributable to a vaccine serogroup, persons who travel to or reside in countries in 
which meningococcal disease is hyperendemic or epidemic, unvaccinated or incompletely
vaccinated first-year college students living in residence halls, and military recruits.
There are now two serogroup B meningococcal vaccines licensed in the US for use in persons
10 through 25 years of age. Trumenba® is a three-dose series and was licensed by the Food 
and Drug Administration (FDA) in October 2014. Bexsero® is a two-dose series and was
licensed by the FDA in January 2015.  Bexsero® was also licensed in several other countries for
use in persons ≥2 months of age.
11 
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The work group (WG) has been discussing a number of different options for use of MenB
vaccines. To address the immediate need of protecting groups at increased risk, the WG
suggested language for vaccination of persons with persistent complement component
deficiencies, persons with anatomic or functional asplenia, microbiologists who are routinely
exposed to isolates of Neisseria meningitidis, and persons identified to be at increased risk
because of a serogroup B meningococcal disease outbreak. The WG also has been reviewing
available data and discussing options for broader use of MenB vaccines in adolescents and 
college students.  Policy options for broader use of MenB vaccines will be discussed during a 
future meeting.
The WG has discussed a number of age-group options for recommendations for persons at
increased risk, including the current licensed age indication for both MenB vaccines, which 
includes persons 10 through 25 years of age.  Additionally, the WG considered language for
persons aged ≥2 months at increased risk as Bexsero® is currently licensed for persons over
age two months in other countries.  However, data are not currently available for use of
Trumenba® in children less than 10 years of age. The schedule and reactogenicity profile for
MenB vaccines are quite different in young children compared to adolescents. The WG plans to
review the data for persons aged 2 months through 10 years, and may propose extended policy
options for persons at increased risk in the future.  During this session, the WG suggested
language for use of MenB vaccines in persons 10 years of age and older who are at increased
risk for meningococcal disease. This extends beyond the licensed age indication, but the WG is
comfortable that there are no theoretical differences in safety for those >25 years as compared 
to those 10 through 25 years of age.
Regarding the groups at increased risk for serogroup B meningococcal disease, persistent or
genetic deficiencies in the complement pathway are well-known to increase risk for
meningococcal disease. These deficiencies are rare and only affect about 0.03%1 of the US
population. Individuals with persistent complement component deficiencies are at up to a
10,000-fold2 increased risk for developing meningococcal disease and often develop recurrent
infection [1P Densen. Complement deficiencies and meningococcal disease. Clin Exp Immunol.
Oct 1991; 86(Suppl 1): 57-62; 2Cohn et al. Prevention and Control of Meningococcal Disease.
MMWR. March 22, 2013; 62 (RR-2)].
Eculizumab (Soliris®) is a monoclonal antibody that is approved for treatment of atypical
hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).  It
functionally creates a complement deficiency by binding to C5 and inhibiting the terminal portion 
of the complement cascade.  Several individuals (n=5/326) in the clinical trials for eculizumab
have reportedly developed meningococcal infections despite prior vaccination with conjugate 
vaccines.  Persons being treated with eculizumab were not explicitly included in the conjugate
vaccine recommendations; however, meningococcal vaccination is required for persons prior to
treatment [http://soliris.net/sites/default/files/assets/soliris_pi.pdf].
Persons with functional or anatomic asplenia also appear to be at increased risk for 
meningococcal disease.  However, the data are less compelling than for pneumococcal disease 
risk1.  This group includes sickle cell disease, which affects approximately 90,000 to 100,000 
persons of all ages2  in the US.  In asplenic persons, the case-fatality ratio is also elevated for 
meningococcal disease (40% to 70%)3. It has been demonstrated that people with asplenia 
have a significantly lower response to one dose of meningococcal C (MenC) vaccine4  [1Cohn et 
al. Prevention and Control of Meningococcal Disease. MMWR. March 22, 2013; 62 (RR-2); 
2http://www.cdc.gov/ncbddd/sicklecell/data.html; 3Updated recommendations for the use of 
12 
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meningococcal conjugate vaccines. MMWR. January 28,2011; 60(3): 72-76; 4Balmer, P et al.
Infection and Immunity, Jan 2004, 332-337].
Microbiologists who work with Neisseria meningitidis are also at increased risk for
meningococcal disease.  In a review by Sejvar et al (2005), 16 cases were reported worldwide 
between 1985 and 2001.  All occurred among clinical microbiologists in medical microbiology
laboratories, with 7 cases due to serogroup C and 9 due to serogroup B. None of the cases in 
the review occurred in persons working in hematology, chemistry, or research laboratories.  Of 
the 16 cases, 8 (50%) were fatal, and 15 occurred in microbiologists who had performed strain
manipulation on an open laboratory bench.  Since this review, 6 additional cases of
meningococcal disease have been reported in microbiologists. Of these, 2 occurred in the US
and 1 each occurred in New Zealand, France, Sweden, and Argentina. These cases included 
cases in industry and research microbiologists [Sejvar et al. Assessing the risk of laboratory
acquired meningococcal disease. J Clin Microbiol 2005; 43:4811-4. CDC. Laboratory-acquired 
meningococcal disease – United States, 2000. MMWR 2002;51:141-4. Borrow et al. Safe
laboratory handling of Neisseria meningitidis. J of Infection 2014; 68:305-312].
The Sejvar paper estimated an attack rate of 13/100,000 among microbiologists who work with 
Neisseria meningitidis1. The high case fatality ratio observed among microbiologists who have 
developed meningococcal infection is likely due to exposure to high concentrations of
organisms and highly virulent strains. The majority of cases have occurred among clinical
microbiologists who were not using respiratory tract protection at the time of exposure.
The final group includes persons at risk because of a serogroup B meningococcal disease 
outbreak. Fortunately, meningococcal outbreaks are rare, historically causing only about 2% to
3% of US cases1. However, five serogroup B clusters/outbreaks have been reported on college 
campuses during 2009 through 2013.  In two of these recent outbreaks, students were 
estimated to be at a 200- to 1400-fold increased risk for meningococcal disease during the
outbreak period.  In the recently published guidance for serogroup B meningococcal outbreaks
in institutional settings, the thresholds for considering vaccination were defined as 2 cases in 
institutions with populations less than <5,000 persons and 3 cases in institutions with 
populations of ≥5,000 persons2 [1 National Notifiable Diseases Surveillance 
System2http://www.cdc.gov/meningococcal/downloads/interim-guidance.pdf].
During the first two months of 2015, two outbreaks of serogroup B meningococcal disease were 
reported on college campuses in the US.  Two cases occurred among students at a Rhode 
Island college, which has 4500 students.  A vaccination campaign was conducted in response 
to the cases using Trumenba®, and approximately 98% of the target population received Dose 
1.  Four cases of serogroup B meningococcal disease have been reported at an Oregon 
university with 25,000 students, including one death.  Two of the four cases were 
epidemiologically linked, but were not close contacts with one another.  Planning is currently 
underway for a MenB mass vaccination campaign scheduled to begin on March 2, 2015.  
Additional sporadic cases of serogroup B meningococcal disease in college students have also 
been reported to the CDC this winter. 
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The following table summarizes the risk groups and includes the available data on cases that
have occurred in each of the risk groups:
Approximately 300,000 to 350,000 individuals fall into these groups.  Although only a handful of
cases have been documented in Active Bacterial Core surveillance (ABC) or the published 
literature, these groups are well-known to be at increased risk for meningococcal infection and 
are currently recommended to be vaccinated with meningococcal conjugate vaccine, but remain 
at risk for serogroup B meningococcal disease.
Three groups are included in the current conjugate vaccine recommendations but are not
proposed to be included for MenB.  First-year college students living in residence halls are not
included because they are being considered in the broader adolescent and college student
policy options. Travelers are also not being considered because their risk is primarily due to 
serogroups other than B.  Military recruits are not being considered because the current MenB
epidemiology in the military is similar to the US population1 and the Department of Defense 
(DoD) sets its own vaccination policies [1Broderick M, et al. Incidence of Meningococcal Disease
in the United States Military Before and After Adoption of the Conjugate Vaccine (MCV-4). EID.
Feb 2015].
In summary of the available immunogenicity and safety data, both of the MenB vaccines have a 
demonstrated immune response in the general adolescent population.  Nearly all adolescents in 
clinical trials achieved protective antibody titers after either three doses of Trumenba® or two 
doses of Bexsero®.  For Bexsero®, response rates were somewhat lower in a small study
conducted among US and Polish adolescents.  However, it is important to remember that
immunogenicity data are not directly comparable for Trumenba® and Bexsero® in part because
the primary endpoints differed for each of the vaccines.  Immunogenicity data are not currently
available from persons in most of the groups at increased risk, although limited data are 
available for use in laboratory workers. Only limited short-term (18 through 23 months) antibody
persistence data are available for Bexsero®.  Persistence data for Trumenba® should be
forthcoming shortly, which will be important for informing booster recommendations for these
groups at increased risk in the future.
Several pieces of additional data are needed for both vaccines to inform policy decisions,
including immunogenicity against additional strains to evaluate breadth of coverage, antibody
persistence data, safety and immunogenicity data (concomitant vaccination, groups at
increased risk, other age groups), and additional safety data.  A number of these studies are 
ongoing, and data will be reviewed by the WG when available.
14 
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New data on the safety and immunogenicity of concomitant administration and the safety and 
tolerability of Trumenba® have become available since the October 2014 ACIP meeting.  A
detailed description of the newly available data for Trumenba® was provided to the voting 
members of ACIP. The safety and immunogenicity of concomitant administration of Trumenba® 
with Menactra® and Adacel® were evaluated. The local and systemic reactogenicity profiles
were demonstrated to be similar when Trumenba® was administered alone or concomitantly
with the other vaccines. In addition, non-inferior immune responses to all Tdap and MenACWY
antigens and the MenB test strains were observed.
In a large-scale safety study which evaluated the safety and tolerability of Trumenba®, the 
safety profile observed was consistent with studies that supported licensure. There are limited 
plans for both manufacturers to collect immunogenicity data from persons in the groups at
increased risk.  A small immunogenicity study is currently underway for 150 persons 2 through 
17 years of age with complement component deficiencies and asplenia receiving two doses of
Bexsero®.  Data from this study are anticipated to be available in 2016.  In addition, small
studies are currently ongoing for both Trumenba® and Bexsero® in laboratory workers.
In summary of safety, MenB vaccines are more reactogenic than other vaccines given during 
adolescence.  However, the majority of local and systemic reactions to the MenB vaccines are 
mild to moderate in severity and are transient, with the most common adverse event (AE)
reported being pain at the injection site.  Serious adverse reactions (SAEs) are rare, and rates
are similar between vaccine recipients and controls in the clinical trials.  Safety data specific to
the groups at increased risk are not currently available, but are anticipated to be similar to the
general population.
In terms of other sources of safety data for MenB vaccines, there is limited experience outside
of clinical trials.  Most of this experience is with Bexsero®, which has been administered to 
approximately 17,000 persons vaccinated under an expanded access Investigational New Drug 
(IND) program for outbreak response at two US universities and in over 40,000 persons
vaccinated in a regional public health program in Québec.  No concerning patterns were 
observed among AEs following any of the vaccination programs.  For Trumenba®, no post­
licensure safety data are currently available, but it is CDC’s understanding that safety data are
being collected for Trumenba® in conjunction with the two current outbreak responses in Rhode
Island and Oregon.
The WG also reviewed data on theoretical concerns from mouse models about the potential for
development of autoimmune disorders following MenB vaccination.  The FDA also reviewed 
these data, and did not observe any differences in the rate of autoimmune disorders between 
vaccine recipients and controls in the safety studies that supported licensure. Post-licensure 
safety surveillance will be conducted to detect potential safety signals.  However, a large
number of doses must be administered to detect any potential safety signals in the Vaccine 
Safety Datalink (VSD). In the meantime, passive reports to the Vaccine Adverse Event
Reporting System (VAERS) will be monitored.
In summary of the GRADE evaluation outcomes, as a reminder, the first step in the GRADE
process is to formulate the study questions. The following initial study questions were agreed
upon by the Meningococcal WG, although Ms. MacNeil focused only on the last two during this
session:
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Questions Population
1. Should MenB vaccine be 
administered routinely to all
adolescents and young adults? 
Adolescents and young adults 10 through 25 
years of age 
2. Should MenB vaccine be 
administered to college 
students to prevent outbreaks? 
College students 15 through 25 years of age
3. Should MenB vaccine be 
administered to persons at
increased risk for serogroup B
meningococcal disease?
Microbiologists, persons with persistent
complement component deficiencies or
functional or anatomic asplenia (including
sickle cell anemia)
4. Should MenB vaccine be 
administered during outbreaks?
Individuals at increased risk for serogroup B
disease because of an outbreak
The outcomes that were ranked as critical for each question by the Meningococcal WG included 
the following:
 Burden of disease
 Mortality of disease
 Long-term sequelae
 Serogroup B strain coverage
 Short-term immunogenicity
 Persistence of immunogenicity (1 to 2 years after vaccination)
 Serious adverse events
The first four outcomes cannot be assessed in GRADE because they are surveillance data.
These outcomes were evaluated using a modified assessment, and the last three outcomes
were assessed using GRADE. In GRADE, all of the available data for each outcome are 
evaluated on the following six criteria to determine whether the overall evidence type is moved 
up or down and a final evidence type is assigned:





 Other considerations (strength of association, dose gradient, direction of all plausible 
residual confounding)
Given the time constraints during this meeting, Ms. MacNeil reviewed only the available data 
that were used to assess the benefits and harms for each vaccine, and the final evidence type 
assigned to each MenB vaccine for use in persons at increased risk and in outbreak settings.  A
copy of the full presentation for the GRADE evaluation was provided in the ACIP members’ 
binders.
For Bexsero®, a total of six studies were reviewed, including two open-label studies and four
randomized-control trials. The majority of the studies assessed several outcomes.  Four of the 
studies have been published.  However, data were also used from additional unpublished 
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studies. In addition, safety data from three vaccination campaigns were reviewed for SAEs.
For Trumenba®, a total of eight studies were reviewed, including three open-label studies and
six randomized-control trials.  The majority of the studies assessed several outcomes.  Results
of three of the studies have been published.  However, additional unpublished data were also 
used.  Antibody persistence data are not yet available for Trumenba®, so they were not
assessed in this evaluation.
The overall evidence type for use of Bexsero®  among persons at increased risk for serogroup B 
meningococcal disease was graded as Type 3, and among outbreak at risk populations as Type 
2.  The overall evidence type for use of Trumenba®  among persons at increased risk for 
serogroup B meningococcal disease was graded as Type 3, and among outbreak at risk 
populations as Type 2.  Based on the available data and evidence reviewed, the WG supports 
routine vaccination of persons at increased risk for meningococcal disease for several reasons, 
including the demonstrated disease risk in the specific risk groups and that these groups are 
currently recommended to be vaccinated with MenACWY conjugate vaccines.  Additionally, 
there is a demonstrated immune response to MenB vaccines in the general adolescent 
population and there are no theoretical safety concerns for persons >25 years of age from 
vaccination as compared to persons aged 10 through 25 years. 
The WG also supports harmonization of the current MenACWY conjugate vaccine 
recommendations with the proposed MenB language in two areas where the language differs.
First, use of eculizumab (Soliris®) will be explicitly included as an indication for vaccination with 
MenACWY conjugate vaccine.  Secondly, the wording for the use in outbreaks will be aligned 
with the proposed wording for MenB vaccines to read, “Persons identified to be at increased risk
because of a meningococcal disease outbreak attributable to serogroups A, C, W, or Y.” The
two sets of recommendations would still differ for certain special populations (e.g., travelers,
first-year students living in residence halls, and military recruits) who are not included in the 
proposed MenB language.
The WG’s proposed language for use of MenB vaccines for persons at increased risk was as
follows:
A serogroup B meningococcal (MenB) vaccine series should be administered to persons
aged ≥10 years at increased risk for meningococcal disease. (Category A) This includes:
 Persons with persistent complement component deficiencies1 
 Persons with anatomic or functional asplenia2 
 Microbiologists routinely exposed to isolates of Neisseria meningitides
 Persons identified to be at increased risk because of a serogroup B meningococcal
disease outbreak
1Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or
taking eculizumab (Soliris®)
2Including sickle cell disease
17 
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In addition, the following guidance for use was proposed:
 Depending on the MenB product used, a complete two- or three-dose series of vaccine 
is required for protection from serogroup B meningococcal disease.
 The same vaccine product should be used for all doses.
 No product preference is to be stated.
In conclusion, Ms. MacNeil thanked the members of the ACIP Meningococcal WG for the
dedication and thoughtful discussions over the last several months as they quickly worked 
through a review of the available evidence for these new MenB vaccines.
Discussion Points
Regarding the differences between the quadrivalent MenACWY and the B vaccine and 
recognizing that the military sets its own vaccination policy, Dr. Reingold asked whether it was
generally envisioned that differences between use of the B vaccine and use of the quadrivalent
in terms of travelers and college students would remain differences in terms of how the two 
vaccines are used.
Ms. MacNeil responded that the differences would remain. The plan is to consider adolescents
and college students in June 2015 as part of the broader recommendations.  But, the 
differences for travelers and the military would remain.
Dr. Harriman asked whether the WG would also consider the use of B and MenACWY
meningococcal vaccines for infants, noting that the Affordable Care Act (ACA) requires that
Category A and B recommendations be covered.
Dr. Rubin replied that the WG intends to consider MenACWY use in infants during future 
deliberations.
Dr. Sawyer (PIDS) requested clarification regarding why the use for high risk begins at age 10 
as opposed to a younger age, given that one of the vaccines is licensed for use in children 
younger than 10 years of age.
Ms. MacNeil indicated that currently in the US, the minimum licensure age is 10.  Bexsero® is
licensed down to two months of age in other countries. The WG will eventually review this
issue.  For this vote, they only wanted to propose the recommendation for 10 years of age and 
older.
Dr. Harrison asked what is being done specifically to monitor safety in the context of these 
vaccines during outbreaks, and what the DoD’s protocol is in terms of using these two vaccines.
Ms. MacNeil replied that when the vaccine was used under an IND, as part of the IND, a 
specific safety follow-up was done.  Her understanding is that this is also being done for
Trumenba® in the two current outbreaks, although CDC is not involved in those investigations.
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Dr. Sergienko (DoD) responded that MenACWY vaccine is currently being administered. The
Joint Preventive Medicine Working Group met last month to discuss MenB vaccine, and they do 
not think there is an indication for administering that in the recruit population at this point.
Dr. Duchin (NACCHO) asked whether the threshold for vaccination for use of the MenB vaccine 
as currently stated for the IND would remain the same for the vaccine if a vote was taken to 
approve the use of that vaccine in outbreak settings.  He also inquired about what is known 
regarding the impact of the vaccine on carriage.
Ms. MacNeil responded that the thresholds for the use of MenB vaccines in institutional settings
under an IND are being used for the current outbreak, which will likely continue in the near-term.
There are plans to review the entire outbreak guidelines and present results during the October
2015 or February 2016 ACIP meeting. While little is known about carriage, carriage studies will
begin at the universities currently experiencing outbreaks.  Hopefully, there will be more data 
regarding carriage available by the June or October 2015 ACIP meeting.
In the spirit of full disclosure, Dr. Temte emphasized that recommendations for a universal
vaccination would be discussed during the June 2015 ACIP meeting.
Public Comments:  High Risk MenB Recommendations
Dr. Mary Ferris
Student Health Director
University of California Santa Barbara
We have a campus of 30,000 students, faculty, and staff.  In November 2013, our campus
community was devastated by an outbreak of four cases of meningococcal serogroup B disease 
within a 10-day period.  It resulted in life-threatening complications to our first case of a 19 year
old lacrosse team member who suffered amputations to both legs and has extensive skin grafts
and scarring, but did survive.  So, I know you’re aware of the devastating consequences of this
terrible disease.  But, you may not know the impact it has on a university when an outbreak
occurs.  National news outlets camped out on the campus. There was widespread fear and 
even panic among the students, faculty, staff, and the surrounding city. The local school district
initially prohibited our student teachers from their sites.  Parents drove in to take their children 
back home. Our campus childcare center refused to have the student volunteers there.
Parents demanded we close the campus, but did not want their students to come home for the
Thanksgiving holiday. It was really terrible for all of us, as you can imagine.
Our local public health department and the CDC helped us and established special phone lines
to handle the high volume of increasing distress calls. We greatly appreciate all the help they
gave us.  And as you know, we were able to obtain the MenB vaccine through a special FDA
approval with the assistance of the CDC.  But, we would have preferred to avoid this disaster
completely by protecting our students in advance with a vaccine that covers MenB.  So, we’re 
glad to have your approval of the vaccine for outbreak settings, but we think that we would 
benefit even more if our students came to campus already protected by the vaccine. Outbreaks
will happen again, and as you are hearing, it’s currently going on at the University of Oregon,
and they’re struggling to find a source to pay for those vaccines.  Even one case in a college 
setting has major repercussions on the institution, and most colleges will not have the resources
to pay for vaccines when these outbreaks occur.
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We need the ACIP to establish MenB vaccine as part of routine adolescent immunizations so 
that our entering students can be protected before they arrive on campus and are exposed to
meningococcus, not just after an outbreak occurs. We also can benefit from your
recommendation for pre-entry vaccination so that we can enforce that in our entry immunization 
requirement before students even get to campus.  The majority of our students are first-
generation college students, coming from low-income families, and do not have the ability to
afford this vaccine unless it’s covered by health insurance, which, as you know, follows your
recommendations. Thank you for allowing me to speak.  I sincerely hope you’ll consider the




Global Healthy Living Foundation (GHLF)
I have no disclosures to make today.  GHLF receives funding through grants and partnerships
with industry, private foundations, as well as the government. I’m here today on behalf of Dr.
Neal Raisman, who was here down from Columbus yesterday and, unfortunately, needed to 
return to an urgent issue back at home.  So, instead I’ll read his brief comments here, and I will
not attempt his Boston accent.
My name is Neal Raisman.  In 2005, I was the father of two.  Today, I am the father of
one.  On the morning of September 27th, my youngest son, Isaac, woke with a 
headache and was dead of meningococcal by 4:30 the same day.  I found his body.  He 
had less than 12 hours from the time he told us he had a headache until he died, and a 
vaccine would have prevented his death.  It’s an epidemiological story you all know too
well, but it's a personal story I never wanted to know.  Today I’m here as a spokesperson 
for the Global Healthy Living Foundation, and together we are asking this committee to
endorse the FDA labeling recommendation, which is for immunization to prevent
invasive disease caused by Neisseria meningitidis serogroup B for individuals 10 
through 25 years of age.
My words here today and your committee meeting could not come at a more immediate
time.  As you know, eight days ago, Lauren Jones, a student at the University of Oregon,
added her name to the list of those who have died of meningitis. Just three days ago, a 
UC Davis student was diagnosed with meningitis.  At the University of Oregon, students
who have the money will be able to get the vaccine for meningitis B and those who do
not will remain exposed to its ravages.
Since the FDA approved vaccine for meningococcal strain B in November of 2014,
people have died.  Did they die because the ACIP didn’t act?  Perhaps.  Although the
vaccine was available to those who could afford to pay for it, without your
recommendation, as you know, insurance companies and Medicaid won’t cover the cost.
It’s not difficult to conclude that informed people with the money to pay for the vaccine 
have lived and those who can’t afford it or don’t know about it have died. This is counter
to everything the ACIP, the CDC, the FDA, and, of course, the NIH stand for.  Your
endorsement vote for the FDA recommendation would realign this committee with its
mission and with the values and expectations of parents with college-aged children. We 
expect the government to tell us when the health of our children is in danger and then
help us decide what to do about it.
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Because meningitis is nearly always fatal, the low numbers of people affected mask the 
toll these cases take on families, such as mine, and on our communities. My job today
is to help you understand the depth of the emptiness that we parents feel every day and
the heartache we feel for those parents who are about to join our ranks—the ranks of
families minus one.  Please act so other young people and their families are not so 
violently affected by meningitis.  Please act so there are no more Isaacs and Laurens.
Thank you very much.
Dr. Susan Even
ACIP Liaison
American College Health Association
I just wanted to speak on behalf of the American College Health Association (ACHA), which is
very aware of the devastating physical and emotional impact of meningococcal disease on the
individual college student and their families, and the campus communities in sporadic cases and
outbreaks, as have been eloquently described. The American College Health Association is
committed to promoting implementation of CDC’s immunization recommendations on college 
campuses, including pre-matriculation meningococcal conjugate vaccine (MCV4).  Now that
MenB vaccines are licensed and these cases continue to arise, ACHA appreciates being 
involved in the ongoing discussion regarding use in outbreaks, appreciates the impact that this
guidance will have in promptly responding to this challenging situation, and also supports
prompt deliberations and an expeditious decision regarding the general recommendations for
MenB vaccine so information will be available to parents, families, students, and campuses for
the students entering in the fall of 2015. Thanks.
Dr. Romero made a motion to approve the MenB vaccines recommendation for persons aged  
≥10 years at increased risk for meningococcal disease.  Dr. Kempe seconded the motion.  The 
motion carried with 15 affirmative votes, 0 negative votes, and 0 abstentions.  The disposition of 
the vote was as follows: 
15 Favored: Bennett, Belongia, Bocchini, Campos-Outcalt, Harriman, Harrison, Karron, 
Kempe, Pellegrini, Romero, Reingold, Riley, Rubin, Temte, and Vazquez 
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Vaccines for Children
Dr. Jeanne M. Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Santoli explained that the purpose of this revision was to update the resolution to: (1) clarify
eligible groups for meningococcal conjugate vaccines; (2) streamline the schedule and interval
information for meningococcal conjugate vaccines by incorporating links to published 
documents; and (3) add meningococcal serogroup B vaccines recently licensed for use. The
following minor clarifications in language were proposed (changes were shown in yellow in the 
presentation, but are underlined in this document):
Meningococcal Conjugate Vaccines (MenACWY and HibMenCY)
Eligible Groups:
 Children aged 2 months through 10 years who are at increased risk for meningococcal
disease attributable to serogroups A, C, W, and Y, including:
Children who have persistent complement component deficiencies (including
inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D or 
taking eculizumab [Soliris®])
Children who have anatomic or functional asplenia, including sickle cell disease
Children traveling to or residing in countries in which meningococcal disease is
hyperendemic or epidemic, particularly if contact with local population will be 
prolonged
Children identified to be at increased risk because of a meningococcal disease 
outbreak attributable to serogroups A, C, W, or Y
 All children aged 11 through 18 years
Recommended Vaccination Schedule and Intervals:
Recommended schedules and intervals for meningococcal conjugate vaccines can be




Refer to product package inserts.
Contraindications and Precautions
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Serogroup B Meningococcal Vaccines (MenB)
Eligible Groups:
 Children aged 10 through 18 years at increased risk for meningococcal disease 
attributable to serogroup B, including:
Children who have persistent complement component deficiencies (including
inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D
or taking eculizumab [Soliris®])
Children who have anatomic or functional asplenia, including sickle cell
disease
Children identified to be at increased risk because of a meningococcal
disease outbreak attributable to serogroup B
Recommended Schedule and Intervals:
Recommended Dosage:   
Refer to product package inserts.   
Contraindications and Precautions: 
Contraindications and Precautions can be found in the package inserts available at
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833
The following language would appear at the end of the recommendation: 
 
[If an ACIP recommendation regarding meningococcal vaccination is published within 12 
months following this resolution, the relevant language above (except in the eligible 
groups sections) will be replaced with the language in the recommendation and 
incorporated by reference to the publication URL.] 
Discussion Points
In terms of eligible groups, Dr. Bocchini requested clarification regarding HibMenCY vaccine,
which is not a travel vaccine and would not be recommended for children who are traveling
because it does not include A.
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Dr. Santoli replied that the eligible groups section could be amended to make that more clear.
Vote:  VFC Resolution for MenB Vaccines for Persons Aged 
≥10 Years at Increased Risk for Meningococcal Disease
Dr. Harrison made a motion to approve the VFC MenB vaccines recommendation for persons 
aged ≥10 years at increased risk for meningococcal disease.  Ms. Pellegrini seconded the 
motion.  The motion carried with 15 affirmative votes, 0 negative votes, and 0 abstentions.  The 
disposition of the vote was as follows: 
15 Favored: Bennett, Belongia, Bocchini, Campos-Outcalt, Harriman, Harrison, Karron, 
Kempe, Pellegrini, Romero, Reingold, Riley, Rubin, Temte, and Vazquez 
 
0 Abstained:   N/A
   
Additional Meningococcal Vaccine Public Comments
Frankie Milley
Founder / National Director
Meningitis Angels
At the time my son, Ryan, got meningitis, there was a vaccine but there was no marketing, there 
was no recommendation, and there was no accessibility, so he died. With permissive 
recommendations, he still would have died because we still wouldn’t have known about it.  You
know, to me, this is like if you have a ship with 100 passengers on board, you have 100 life 
vests and that ship is sinking, you’d hand out 50 of those life vests and the other people watch 
theirs hanging in the closet as they drown.  You’ve done a great job in protecting these kids so 
far from this disease. We’ve got half of the puzzle there. We need to finish the puzzle.  I am
really encouraging you, as you move forward, to work fast on this because I really believe a 
permissive recommendation in an outbreak—somebody’s going to die before that happens or
be left debilitated. That’s wrong. We shouldn’t have to have a sacrificial lamb. I would 
encourage you to move away from those living in dorms. We’ve been fighting this 10 years and 
we still argue with physicians every day that they don’t have to live in a dorm to get this.  Five of
our kids were told, “You don’t live in the dorm.  You don’t get the vaccine.”  All five of them died.
So, I just want to encourage you to really think about moving fast on this issue so other kids
don’t die.  Thanks again.
Scott Parkhurst
Meningitis Angels
My son Jake is the youngest of two of my boys. He was an A student Junior in high school.  He 
loved golf.  He skied, snowboarded, and rode motorcycles.  He was into baseball. I got a call
Saturday night about a year ago to the day that he wasn’t feeling well.  He was with his mom
and I said, “Drink your fluids and we’ll see how you feel in the morning.” The next morning, I
texted him to follow up on how he was feeling, and he said his mom was taking him to urgent
care.  At 10:30 Monday morning, I texted his mom and she said was being put in an ambulance 
to take him to the hospital. I drove to the hospital. I was in the ER and the doctor pulled me 
and his mom aside and said, “He may not make it.”  I said, “Fight for your life” and he nodded
his head. They took him to ICU and he was in a medically-induced coma. They had to help him
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fight with antibiotics.  Later that evening, they noticed that one of his pupil’s was dilated and they
thought there might be some brain issues, and so they started to wean him off of the
medication.  He wasn’t showing any responsiveness, so they did an EEG and determined that
he was brain-dead. Jake was dead in 36 hours—cause of death, Meningitis B.  I took my oldest
boy to Canada to get him vaccinated for Meningitis B. I believe a permissive recommendation 
would be the death of Jake all over again. Thank you.
Andy Marso
Meningitis Angels
I prepared some remarks, but obviously, I just kept paring them down and paring them down. In 
the interest of time, I wrote a 270-page book about my experience, so if you want it, Dr.
Pickering has a copy.  Really, the time element here doesn’t necessarily matter because no 
matter how much time I had, I wouldn’t have been able to convey to all of you the horror of
going from a completely healthy college student to within 24 hours being life-flighted on a 
helicopter to a Level 1 trauma center with my lungs failing and struggling to breathe. I wouldn’t
be able to convey to you what my parents felt when they arrived that night, and I was already
unconscious, and the doctors told them I might not survive.  I wouldn’t be able to convey to you 
the deep distress of waking up from that coma three weeks later and realizing I couldn’t move 
my hands and feet, and having doctors remove the bandages to show me that my arms and
legs were rotting while still attached to my body. I would not be able to convey to you the pain 
of the next three months, both physical and emotional, that I spent in a burn unit at KU Medical 
center having my arms and legs debrided daily.  I would not be able to convey to you the post-
surgical pain of amputations that were still necessary to my feet and hands.  I would not be able 
to convey to you the frustration of the year of physical and occupational therapy that I needed to
be able to wipe myself and feed myself as a 23-year old man.
No matter how much time you could give me, it would not repay my father’s insurance company
for the $2 million in medical bills that we billed them that first year.  It would not compensate me
for all of the thousands in out-of-pocket costs I have paid every year since for my medical
needs, including my prosthetics to walk and to stand. Those costs will be with me for the rest of
my life. When you consider these recommendations, please consider not just the costs, but the 
cost burden.  Mass vaccination spreads that cost burden equitably among a large population.
Neglecting to vaccinate large populations concentrates the cost burden for this disease on
families like mine, and it is enormous. The recommendation that you all made today is a start,
but it’s barely a start. What it basically says is that if you go to a school like the University of
Missouri where they just had a confirmed MenB case, you’ve got to wait for two more people to
get sick because that’s a big school.  So, they’re not going to bring in the vaccine until at least
two more people critically ill.  That’s not acceptable. That’s not preventative medicine. That’s
crisis management, and it’s not even very effective crisis management.  I would much rather
see us prevent this before it happens.  So, what I encourage you all do is be bold and consider
your legacy. We have a chance to wipe out a disease that causes incalculable human suffering.
One of the most important pieces of that puzzle is your recommendation. Thank you.
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Lynn Bozof

National Meningitis Association (NMA)
 
I have no disclosures to make.  As many of you know, NMA is comprised of survivors and 
families who have all suffered tremendously from meningococcal disease. In January, NMA
hosted a round table of survivors, their family members, infectious disease specialists, college
health officials, and others who could all offer a unique perspective and knowledge about
meningococcal disease. We would like to share the outcome from that meeting, which is in your
packet and also is available on the back table.  It gives voice to the concerns and worries of the
participants.  The report points out the long-term impact on survivors, the life-altering changes
for all of their families, and the effects on an entire community long after the immediate impact.
So, as others have said, as you consider serogroup B recommendations in light of all of the
cases and outbreaks that have occurred recently, please consider these life-altering and life-
changing perspectives. I’ve heard from so many families who have lost children to the B
serogroup who thought their children had been protected because they had been vaccinated 
according to CDC recommendations. We now have the tools to protect against the most
common strains of this disease. We need to do the right thing and routinely recommend 
vaccination for adolescents and teens. It’s the only way that parents who rely on physician 
recommendations can have the opportunity to fully protect their children. Thank you. We have 
a short PSA to show.
Patty Wukovits

National Meningitis Association (NMA)
 
In 2012, my beautiful daughter, 17 year old Kimberly, a healthy high school senior in New York,
died of serogroup B meningococcal disease just one week before graduating. We buried her in
her prom dress just two days before she would have been able to wear it at her prom.  I’m a
nurse, and when Kim got sick, I was sure it wasn’t meningitis because she’d been vaccinated. I
assumed that the recommended vaccine covered it all and I thought she was safe.  After losing 
Kim, I dedicated myself to learning more. There were no approved serogroup B options then,
but there are now.  Please try to think about the message that parents will hear, “The CDC
recommended that your child be vaccinated against meningococcal disease, but this vaccine 
won’t protect against all strains of the disease. There is an additional vaccine that protects
against the strain most common in adolescents. It is not recommended, but your child can get it
if you want it and if you’re able to obtain it.”  As a health care professional, this is an extremely
complicated message to deliver and, more importantly, it’s a hard message for a parent to hear
and understand. We cannot expect parents to know that their children are not protected against
serogroup B, and we cannot expect health care providers to act without strong guidance from
this committee. That’s why I’m asking you to consider broad recommendations for this vaccine.
A recommendation would make it easy for parents to do the right thing to vaccinate their
children. The bottom line is Kimberly would be alive today if she had had the opportunity to
have been protected by the B vaccine.  Instead, as her mother, I am standing here literally in 
Kim’s shoes, the very shoes she should be wearing right now in her third year of nursing school
fulfilling her dreams to become a pediatric nurse.  Please help ensure that all children get the
protection they need so that what happened to my family and to Kimberly does not happen 
again. Thank you.
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Carl Buher
 
National Meningitis Association (NMA)
 
Thank you guys. I’m so grateful to have the chance to speak here today representing the
National Meningitis Association.  I survived bacterial meningitis when I was 14, and just last
year learned that it was serogroup B. I spent five months in the hospital, lost three of my fingers
and both of my legs below the knee on Halloween.  I had 11 surgeries.  It took me almost four
years to learn to walk again on my prosthetics. To date, my medical bills have far exceeded $2
million, but I still consider myself lucky.  Eleven years later, I have a college degree, a great job,
and a beautiful wife.  Most survivors I know feel the same way. We have pretty good attitudes
and have been able to find the positives in this disease.  For example, my wife and I like to talk
about my perks list, which includes things like my feet no longer fall asleep and the ability to
know exactly what shoe size I need.  However, there are also some cons. I can no longer enjoy
fuzzy slippers and Ziploc® bags have become my worst enemy.  But no matter how lucky we 
are, most of us will deal with the effects of this disease for the rest of our lives. My fellow
survivor, Samantha, has had more than 37 surgeries in 30 year and still has pain on a daily
basis.  Kyla lost both legs and most of her fingers and has gone through a dozen surgeries in 
recent years to lengthen her thumb, because she says “opposition is everything.”  Blake learned 
so much as an outpatient before a transplant that he became a dialysis nurse.  Some of us, Like 
Francesca, have invisible scars like the loss of cognitive function, or hearing, or vision.  Many of
us endured and some continue to endure anxiety, fear, and depression because of this terrible 
disease. When we get together, we talk about the challenges we deal with that most people 
don’t even think about, like how to take a shower when you’re traveling with no legs or how hard 
it is to count to 10 on your fingers when you’re missing a few.  For most of us, it will affect our
finances for the rest of our lives. Our cost of living will always be higher, and we may need 
additional support and more obvious things, such as needing more time off work to deal with 
additional surgery or complications.  Even with great insurance plans, we pay enormous co­
pays and out-of-pocket expenses for other things no insurance will cover, such as retrofitting 
cars to fit our needs or renovating homes. We are all very different, but one thing we agree
on—we don’t want anyone to have to go through what we went through and still deal with it on a 
daily basis. When you look at the cost of prevention, I hope you’ll calculate how high the cost of




I’m here to support the routine schedule of Meningitis B.  My organization has been around 
since 1899. We are the oldest consumer organization, and we also survey consumers on their
attitudes about vaccines. What we found in our latest survey was that 87% of parents support
getting their children vaccinated.  The disease they fear most that vaccinating can prevent is
meningitis.  So, I’m here also to support the many parents and families who came out at their
own expense.  I come to this as a consumer advocate and wearing several other hats. One is
that I had an uncle who had polio.  He got it the year before the polio vaccine came out, and I
watched my family suffer while he clung to life in an iron lung for two years and then went on to
be a quadriplegic. One year later, this tragic condition could have been prevented. I’m also the 
parent of a college-aged kid who is a baseball player and lives in the dorms.  As I meet with a 
lot of the meningitis victims, we take a very strong stand in favor and in support of safe and 
effective vaccines. I’m finding it very difficult to access that vaccine for him. It would be 
wonderful if this vaccine became part of the routine schedule. They have to order it. They’re 
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not sure which one they want to order. There’s a wealth of confusion.  I’ve had maybe 10 
phone calls and we still haven’t figured out how to get this vaccine.  So, it really isn’t fair for my
son to be the only guy to get it on his campus, which he probably will be. But, you know, I really
feel so strongly that when you have something that’s safe and effective, and thanks to all of you 
for the critically important work that you do, but there’s just no reason why this shouldn’t be part
of the routine schedule. So, I’m really here with lots of hats on, but I think most importantly to
support all of these families—the parents who came forward with these devastating conditions 
as a result of contracting Meningitis B and something that’s totally preventable. Thank you for
giving me the chance to speak. I appreciate it.
Additional Comments
Dr. Temte indicated that four letters pertaining to meningococcal infection and disease were 
submitted, and would be subsumed into the official minutes of the meeting. Those letters follow:
Leslie Maier
National Meningitis Association
Via Letter to Dr. Temte Date 2-24-15
Dear Mr. Temte:
My name is Leslie Maier and I am on the Board of Directors for the National Meningitis Association.  I live in Tucson,
Arizona.  My son Chris was 17 and a senior in high school when he contracted meningococcal disease and died in
less than 24 hours.  The new meningitis vaccine was not available at that time for his age group. I believe he would 
be alive today had it been recommended.
I’m contacting you to request you write a letter to the Centers for Disease Control and Prevention’s Advisory
Committee on Immunization Practices asking them to routinely recommend vaccines to protect adolescents against
serogroup B meningococcal disease.
The FDA recently approved the first vaccines to protect against serogroup B in the United States.  Since 2005, the 
CDC has recommended a vaccine to protect against strains A, C, W and Y, at age 11-12 with a booster dose at age
16.  Many parents with children who suffered from serogroup B did not know that the vaccine their child received did 
not protect them against it.
Serogroup B meningococcal disease was also the cause of recent college outbreaks at Princeton University and 
UCSB.  In the last 5 months, at least 2 other college students, in cases unrelated to these outbreaks, died from
serogroup B.  In the past month there were at least 5 more cases reported on college campuses across the United 
States.
I am one of the people affected by this horrible disease.  My son’s death devastated our family and community.
Chris’ high school classmates had difficulty finishing their final year of high school.  His sister became an only child 
and is saddened that her new son will never have nieces or nephews to grow up with.  His father and I have 
experienced the greatest loss possible, that of our child.  Our goal is that no one else has to experience this terrible 
disease. We share our story to educate others about meningococcal disease, stressing the importance of
vaccination.
A routine recommendation of serogroup B vaccines for adolescents would be a significant step forward in protecting 
them from this devastating disease.  As someone whose life was profoundly affected by this disease, I encourage 
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February 20, 2015 
Dr. Tom Frieden 
Director
Centers for Disease Control and Prevention 
1600 Clifton Road 
Atlanta, GA 30329-4027 
Dear Director Fieden:
Our organizations, which together represent low-income and minority communities
frequently disadvantaged in access to quality medical care, are writing as members of the Health
Disparities Working Group. We urge you to give the two vaccines for bacterial meningitis
(MenB) currently under consideration by the Advisory Committee on Immunization Practices
(ACIP) a permissive recommendation at the Feb. 25, 2015 meeting.  
The Affordable Care Act contained important provisions intended to address the vaccine
gap in our country. Before passage of the law, this disparity meant vaccines were readily
accessible to affluent communities, while low-income and minority communities lacked 
equivalent access. The National Institutes of Health (NIH) has identified access to vaccines as a 
major factor in curbing health disparities. Studies have found that minorities are less likely to
receive immunizations because of limited access to preventative healthcare and lack of
education on the importance of regular vaccinations. A recent Centers for Disease Control and
Prevention (CDC) report found large racial, ethnic and income disparities in preventable
hospitalizations, where blacks experience a rate more than double that of whites. Preventable
incidents account for more than 1 million hospitalizations each year, at a cost of more than $6.7 
billion annually.  
The Affordable Care Act attempts to equalize vaccine access by requiring that the 
Vaccines for Children Program – which provides approximately 82 million vaccines to 40 
million low-income children each year – cover vaccines to which ACIP has given a permissive
recommendation. Private insurance must follow suit. But if ACIP only approves the vaccines for
certain groups deemed high-risk or following an outbreak, vulnerable populations simply won’t
have access to the vaccines.
This deadly bacterial strain accounts for about 40 percent of meningitis cases in the
United States. While rare, there have been some 50 adolescents that have been struck with it
each year in recent years. Outbreaks on college campuses have been widely covered in the
media given the deaths and amputations that have resulted. But in addition to college students, 
minority communities are also at great risk. Many low-income black families face key risk
factors for bacterial meningitis, including over-crowding, underlying illnesses and tobacco use. 
Victims of this disease are all too aware of its severity and devastating implications, and
no more families should be put at risk by limiting the recommendation. The United States owes
its most vulnerable citizens a long-term, proactive prevention strategy for MenB, rather than a
reactive one that waits for tragedy before taking action.
Our organizations have sought to raise awareness about the growing disparity in health 
for low-income and minority families in the United States, which NIH recently labeled as one of
the nation's greatest challenges. We strongly support efforts by ACIP to address the current
vaccine gap and the devastating impact it has had on at-risk communities around the country, 
and we urge its members to grant a permissive designation to the MenB vaccines.  
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Sincerely,
MINORITY VACCINE DISPARITIES ALLIANCE
Dr. Christopher J. Metzler, CEO, Fitness, Wellness & Health   
Georgia Buggs, M.P.H, RN, Former member, U.S., Department of HHS, The National Vaccine
Advisory Committee (NVAC)
Cc: Dr. Larry K. Pickering
Executive Secretary




Chair, Influenza Work Group
Dr. Karron thanked the WG for a tremendous effort, particularly over the last couple of months
as they considered a lot of very late-breaking data.  Since October 2014, the WG has engaged
in continued discussion of the effectiveness of live attenuated influenza vaccine (LAIV) and
inactivated influenza vaccine (IIV) for both the 2013-2014 and the 2014-2015 influenza seasons.
The WG has also reviewed data pertaining to the recently approved quadrivalent intradermal
influenza vaccine. In the interest of time, some of the presentations were truncated.  Included 
during this influenza session were updates on the interim vaccine effectiveness estimates for
34 
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the 2014-2015 season, an update on LAIV, and proposed recommendations for the 2015-2016 
influenza season.  Additional information that was not presented was included in ACIP
member’s packets, including an update on influenza surveillance and the new Fluzone® 
intradermal quadrivalent influenza vaccine.
Preliminary 2014-2015 Vaccine Effectiveness Estimates
Brendan Flannery, PhD
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Flannery presented brief updates on influenza vaccine effectiveness (VE) during the current
season, and LAIV and IIV among children and adolescents from the US Flu VE network. The 
updated interim VE estimates were based on 4,913 patients with acute respiratory illness with 
cough of 7 or fewer days duration enrolled from November 10, 2014 through January 30, 2015.
The study used a test-negative case-control design.  All patients were tested for influenza and 
vaccination among influenza positive cases which was contrasted with that of influenza-negative 
patients. Of the enrollees, 67% were influenza negative and 33% were influenza positive. Of 
the influenza positive cases, 94% were type A and all subtyped A viruses were H3N2. More 
than half (n=764) of the H3N2 viruses were genetically characterized at CDC using a novel
pyrosequencing assay that determines genetic group, from which antigenic properties can be
inferred. Of the H3N2 viruses from US Flu VE network participants, 85% belonged to genetic
groups that are generally low reactors with A/Texas/50/2012, while only 15% of H3N2 viruses
were genetically more vaccine-like. Among influenza B cases from the Flu VE network, most
were B Yamagata lineage, the B lineage included in both the trivalent and quadrivalent 2014­
2015 vaccines.
In terms of the early interim VE results from the January 16, 2015 MMWR report, adjusted VE
against A(H3N2) illness was 18% with a 95% confidence interval from 6% to 29%.  None of the
age-specific estimates for A(H3N2) were statistically significant and all confidence intervals
overlapped. There was evidence of higher VE against influenza B viruses.  Adjusted VE against
influenza B for patients of all ages was 45%, with a 95% confidence interval from 14% to 65%.
For the 2014-2015 season, numbers of genetically characterized H3N2 viruses from patients
enrolled in the US Flu VE network were sufficient to provide interim estimates of VE against
predominant genetic groups of H3N2 viruses. Regarding adjusted VE against H3N2 illness for
patients aged 6 months and older, 115 H3N2 viruses were genetically characterized as vaccine-
like groups 3C.3 or 3C.3b, and 39% of these patients were vaccinated this season compared to
57% of influenza-negative patients.  Adjusted VE against vaccine-like H3N2 viruses was 49%,
with a confidence interval from 18% to 69%, suggesting that the vaccines perform better against
vaccine-like viruses.  Of the cases, 624 were due to group 3C.2a and 25 were due to group
3C.3a.  This indicates no or low VE against viruses in these antigenically drifted or low-reactor
groups, albeit with wide confidence intervals. Of note, the reference virus from the 3C.3a group,
the Switzerland virus, was selected for the 2015-2016 influenza vaccines. There is cross-
reactivity from the more common viruses from the 3C.2a group.
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Regarding interim 2014-2015 VE, subjects aged 2 through 17 years of age were included in the
VE analysis for LAIV and IIV among children and adolescents. Children who had received at
least 1 dose of current season vaccine at least 14 days prior to illness onset were considered 
vaccinated for this analysis.  Vaccine type was determined from the medical record if available,
but parent report of vaccine type was used if no medical record documentation was available.
Twelve children with unknown or unreported vaccine type were excluded. Vaccine 
effectiveness was calculated separately for LAIV and IIV, where patients unvaccinated this
season were the referent group.
With respect to the interim adjusted VE estimates against H3N2-positive cases for one or more
dose of 2014-2015 influenza vaccine by vaccine type, adjusted VE for one or more dose of any
vaccine among 2 through 17 year olds was 7% with confidence intervals overlapping zero, or no
effectiveness. Estimates for younger and older children were similar. Analyses for LAIV
excluded children who received IIV.  Similar proportions of influenza-positive and influenza-
negative children received LAIV this season.  Adjusted VE ranged from -20% to -24% with 
confidence intervals overlapping zero, suggesting no effectiveness for LAIV against H3N2
viruses so far this season. Analyses for inactivated vaccine excluded children who received 
LAIV.  Adjusted VE estimates ranged from 15% to 19%, again with confidence limits including
no effect and overlapping with confidence intervals for VE estimates for LAIV.
MedImmune is also conducting an observational study of vaccine effectiveness at four sites in 
the US.  Interim 2014-2015 results from this study were prepared by MedImmune and shared
with CDC for comparison with results from the US Flu VE Network. The study enrolls patients
aged 2 through 17 years presenting with febrile respiratory tract illness of less than 5 days
duration.  Vaccination status is determined by medical record or registries and subjects
vaccinated fewer than 14 days before onset are excluded.  Influenza is confirmed by
polymerase chain reaction (PCR) and influenza PCR-negative subjects are the comparison 
group. This analysis included 988 enrollees.
Regarding the number of influenza-positive cases and influenza-negative controls in each group 
of children and adolescents according to receipt of 2014-2015 influenza vaccine, adjusted VE
for any vaccine against any influenza was 27% with 95% confidence intervals from -1% to 47%.
Adjusted VE for LAIV was 19% and for IIV was 31%, with confidence intervals that included 
zero and that overlapped.  Adjusted VE against H3N2 was 16% for LAIV and 33% for IIV, which 
reached statistical significance. There were too few influenza B cases to produce reliable 
estimates of VE by vaccine type for influenza B in children and adolescents.
In conclusion, low interim VE estimates are consistent with predominance of antigenically drifted 
H3N2 viruses. H3N2 accounted for 95% of influenza-positive cases at US Flu VE network sites,
and more than 80% of genetically characterized H3N2 cases were substantially drifted from the 
H3N2 vaccine virus.  In analyses by a viral genetic group, low or no VE was observed against 
drifted H3N2 viruses. There was limited circulation of vaccine-like H3N2 and influenza B
viruses against which VE was higher. Interim VE estimates from the two studies provide no 
evidence of better protection for LAIV in the 2014-2015 season with the predominance of drifted
H3N2 viruses.  For final season VE estimates from the US Flu VE Network, the plan is to 
complete the genetic characterization of influenza viruses and update VE estimates for LAIV
and IIV with verification of vaccine type and prior vaccination, comorbidities, and further analysis
of differences in circulating viruses by site.
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Dr. Flannery acknowledged the many contributors to the US Flu VE Network at the five 
participating sites, his CDC colleagues, and the investigators from MedImmune who shared
their preliminary data for this presentation.
Update:  Live Attenuated Influenza Vaccine (LAIV)
Kathleen Coelingh, PhD
MedImmune
Dr. Coelingh expressed appreciation for the opportunity to present an update on the
effectiveness of LAIV. The results presented were from an investigation into the observed low
effectiveness of LAIV against the H1N1 strain in 2013-2014 and the actions MedImmune is
going to take to ensure the high effectiveness of LAIV in future seasons. MedImmune has
discussed its findings in detail with the Influenza WG and, at their request, shared an
abbreviated summary during this session.
In summary, moderate to high effectiveness of LAIV was observed for A/H3N2 and B stains in
children in 2010-2011, 2011-2012, 2012-2013, and 2013-2014 and for all matched strains in
prior studies.  However, low effectiveness was observed for A/California H1N1pdm09 strain in US in 
2010-2011 (trivalent formulation) and 2013-2014 (quadrivalent formulation).  MedImmune has concluded 
that this issue is specific for A/California H1N1pdm09 LAIV and may be US-specific as LAIV appeared 
effective in Canada in 2013-2014.
The low effectiveness of A/California LAIV is not explained by manufacturing, poor stability
under recommended storage (36-46°F), antigenic mismatch, prior vaccination, pre-existing
immunity, or vaccine strain interference.  MedImmune’s best explanation is that the A/California 
H1N1pdm09 strain has a unique HA stalk sequence that compromises the stability of its hemagglutinin,
making the strain less fit and more vulnerable to heat degradation. HA heat stability appears linked to
the effectiveness of that California strain because detailed analysis of the available 
effectiveness data shows that vaccine shipping when outdoor temperatures are >80°F
correlates with reduced effectiveness for A/California LAIV, but not other LAIV strains. To
remedy this in the future, MedImmune will replace the A/California LAIV strain with an antigenically
matched strain with a more stable HA.
With regard to recent VE data from recent studies in the US and Canada, in terms of VE against
H3N2 and B strains in children 2 through 8 years of age in the CDC and MedImmune studies
conducted during four recent seasons, LAIV effectiveness was consistently moderate to high 
against H3N2 and B strains in every season. In terms of effectiveness against the H1N1pdm09 
strains, the strain contained in the LAIV was always the A/California strain in all of the studies.
LAIV was effective against H1N1 in the 2009-2010 season, but not in the 2010-2011 or 2013­
2014 seasons. To summarize, in the US, LAIV was consistently effective against H3N2 and B
strains, but had variable effectiveness against the H1N1pdm09 strains.
A different picture was seen in the Canadian studies conducted in 2013-2014 by Dr. Danuta
Skowronski, who kindly shared them with MedImmune.  LAIV was highly effective in Canada 
against any influenza strain in individuals under 20 years of age and in children 2 to 8 years of
age, which was statistically significant.  As noted, 59% of the strains in the study were H1N1.
The results were similar when looking at H1N1pdm09 strains only.  However, due to fewer
cases, these estimates had wide confidence intervals and were not statistically significant.
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These results are supported by the results of a second Canadian study conducted by Jeffrey
Kwong, which he presented during the Canadian Immunization Conference in December 2014.
This was a cluster-randomized trial with LAIV and IIV in elementary school children in Ontario in
2013-2014. The incidence of influenza in the children was significantly lower among LAIV
recipients compared to IIV recipients, indicating that LAIV did protect against the H1N1pdm09 
strain in Canada in the 2013-2014 season. These results support the conclusion that the low
effectiveness of LAIV against the H1N1 strain may have been US-specific.
Dr. Coelingh next focused on the hypothesis that is consistent with all of the data she showed 
and is the most biologically plausible explanation for the low effectiveness of the A/California 
LAIV strain in two recent influenza seasons in the US. It is believed that the unique A/California 
HA stalk sequence explains the low LAIV effectiveness against H1N1 in some of the US
studies. The A/California wild-type and LAIV have a glutamic acid at Position 47, which is
abbreviated E47, in the HA stalk that reduces the HA trimer stability and viral fitness.  E47 is not
present in seasonal viruses and is not prevalent in the current H1N1pdm09 strains. When the 
A/California strain is replaced in the upcoming season with a more recent H1N1 strain, that
strain will not possess the E47 and will have enhanced HA stability and viral fitness.
MedImmune has shown that the E47 sequence significantly reduces infectivity in ferrets and 
increases vulnerability to heat degradation with temperatures between 120 ⁰ and 160⁰F. T 
way to think about these experiments is that it takes more heat to pull apart a stable HA than it
does to pull apart an unstable HA. The A/California LAIV strain with E47 in its stalk is readily
differentiated from other seasonal Type A and B LAIV strains, including LAIV strains with known 
efficacy.  Given the A/California strain’s increased vulnerability to heat degradation,
MedImmune hypothesized that even relatively minor and routine exposures to temperatures
above the recommended storage temperature of 36° to 46°F could lead to potency loss, which 
in turn could lower the real-world effectiveness.
In the normal US distribution process, exposures to temperatures over 70° can occur at multiple 
points after leaving the MedImmune chain of control.  Standard processes permit vaccine 
exposure to room temperature up to 79° for up to two hours after unloading from refrigerated 
trucks at distributors and also while packing out shipments to customers. In fact, MedImmune 
has documented that one of the lots most frequently used in both the MedImmune and CDC
studies in 2013-2014 was outside the refrigerated warehouse for 1 hour and 15 minutes at the
distributor.  MedImmune has recently shown that a 1-log decline in A/California potency occurs
after 24 hours at 91°, and is now studying the impact of shorter term exposures on strain 
potency and infectivity.
In the following graphic, the proportion of MedImmune recipients in the MedImmune and CDC
studies who had H1N1 illness is on the vertical axis. On the horizontal axis is the temperature 
at the distributor sites on the date and time of truck unloading.  Each circle on this graph 
represents a separate lot, and the size of the circle corresponds to the number of subjects
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As illustrated in this graphic, there is a strong and significant correlation between lot
effectiveness and the outdoor temperature when the truck was unloaded at the distributor, with 
a cut point to around 80°. This suggests that the temperature exposure at the distributors
during unloading may have adversely affected the performance of the A/California LAIV strain,
which is consistent with this strain’s increased vulnerability to heat degradation.
A similar association was shown between reduced A/California effectiveness and shipping
during hotter weather, before mid-September.  LAIV effectiveness against H1N1 was low in 
2010-2011 and 2013-2014 in the US when most of the doses were shipped during warmer
weeks before mid-September.  In contrast, LAIV effectiveness against H1N1 was high in 2009­
2010 in the US and 2013-2014 in Canada when doses were shipped in the cooler weeks after
mid-September. This analysis is consistent with the hypothesis that the lower fitness of the
California strain, its vulnerability to high temperature, and its potential exposure to temperatures
above 36° to 46° during distribution reduced the effectiveness of the A/California LAIV strain in 
two influenza seasons.
All of this brought MedImmune to its leading hypothesis that the reduced fitness and increased
vulnerability of the A/California LAIV to heat degradation could explain the variable effectiveness
of LAIV against H1N1 strains.  Critical to this hypothesis is that it is known, from previous
randomized control trials (RCTs), that LAIV efficacy can be significantly reduced at 1-log lower
potency. The key point is that the primary deficiency is the unique characteristics of the 
A/California HA. The recent H3N2 and B strains, which do not have the unique vulnerability of
the California strain, have been effective in all recent seasons. This is consistent with 
MedImmune’s multiple previous RCTs.
Regarding MedImmune’s plans for the 2015-2016 and future influenza seasons, the primary
remedy is to replace the A/California strain in the 2015-2016 vaccine with an antigenically
similar strain with a more stable HA. This strain will not contain the E47 residue, and will have a 
heat tolerance similar to strains with demonstrated effectiveness.
As mentioned earlier, none of the other LAIV strains have been ineffective, even though all of
them were subject to the same distribution process and potential temperature exposures. This
highlights that the normal LAIV strains are really quite resilient, and that A/California is the
outlier in this respect.  Nevertheless, MedImmune is working with its US distributors to eliminate
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any significant exposures above the recommended storage temperature of 36 ⁰ to 46⁰F durin 
shipping and handling.
Going forward, additional effectiveness data are expected for quadrivalent LAIV from several
studies as shown in the following table:
In closing, MedImmune is confident that the replacement of the A/California H1N1pdm09 strain 
with a more robust strain with a more stable HA will result in future effectiveness that is 
consistent with what has been observed previously in LAIV in RCTs, and with what has been
observed for other strains in the recent observational study.
Discussion Points
Dr. Karron requested clarity regarding whether it was correct that during the 2013–2014 season,
the US was using quadrivalent vaccine and Canada, where effectiveness of H1N1 was
demonstrated, was using trivalent vaccine.  However, moving forward, it will be possible to
compare quadrivalent to quadrivalent because all countries are now using quadrivalent.
Dr. Coelingh confirmed that this is correct. To make it easy for everybody, starting with the
upcoming 2015-2016 season, everything will be quadrivalent globally. There will be data from
the 2014-2015 season from other countries using quadrivalent.
Dr. Romero asked what measures are in place to check the stability of future strains, given that
this is probably not just an anomaly and happens more frequently than realized.
Dr. Coelingh replied that MedImmune routinely makes its own strains, so they are responsible 
for ensuring that they choose the absolute best, most optimal strain. While screening for HA
stability was not part of MedImmune’s routine screening as this phenomenon had not been
observed in the past, incoming strains being considered for inclusion in the vaccine are now
being screened.  She referred members to the backup slides in their handouts that showed that
in the laboratory, it is possible to discriminate reliably between strains that have this unique
characteristic and do not have heat stability. Though screening is done by sequence, it is more
important to screen by actual function—to actually pressure-test it in the laboratory to determine 
which strains might be more optimal than others in terms of having better HA stability.
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Dr. Reingold asked what is known about vaccine handling where it is being administered in 
terms of how long it might be left out. This is particularly important, given that vaccine is being
administered increasingly in pharmacies and a variety of other places.
Dr. Coelingh responded that LAIV is quite stable even at 25° or what would be called “room
temperature.”  In the clinic setting, vaccine is very resilient to being left out for a day. While she 
did not have specific knowledge about how vaccine is actually handled by providers, she 
surmised that there is probably an entire range. The goal in MedImmune’s stability program is
always to monitor vaccine at the recommended storage temperature of 2° to 8°, or refrigeration 
temperature, or 35° to 46° F. While MedImmune’s stability program monitors the recommended
storage temperature, they also go outside because it is known that some people like to prepare
for a large clinic and they do not thaw one-by-one.  MedImmune is very careful to ensure
stability under those types of conditions as well.
Dr. Kimberlin (AAP) requested a reminder regarding VE during the 2013-2014 season for 9
through 17 year olds and whether it was statistically significant.
Dr. Coelingh replied that VE trended higher in 9 through 17 year olds than in the 2 through 8 
year olds, which was a surprising finding. The finding was not statistically significant.
Dr. Loehr (AAFP) recalled that Dr. Coelingh mentioned that MedImmune’s hypothesis is that it is
a stalk on the H1N1.  Dr. Flannery's presentation on VE for this year showed that the LAIV was
not working particularly well this year and that it is an H3N2 season.  He requested that Dr.
Coelingh comment on that.
Dr. Coelingh indicated that what she presented during this session showed the occurrence in 
2013–2014 that was related to the stalk sequence. The situation in the current season is
entirely different, wherein the mismatch is significant.  For H3N2 strains, Medimmune has
shown good protection in the past against some of the mismatched strains.  For example, in 
1997, there was Sydney/Wuhan and in the comparative Belshe study in 2004-2005, there was
also an H3 mismatch and the efficacy was really high in the eighties.  Her own thought is that
the kind of protection against a drifted strain that will be seen from any vaccine is dependent
upon the degree of the match and mismatch. There are limits for every vaccine in terms of what
degree of mismatch it is still going to work against.  After all, the vaccine is changed every year
to try to match it, and there is a reason why that is done.
Proposed Recommendations 2015-2016 Influenza Season
Lisa A. Grohskopf, MD, MPH
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Grohskopf acknowledged the Influenza WG members, as well as the many other people 
involved in the work that goes into compiling all of this information.  For this meeting, there were 
two proposed recommendations for the next influenza season:  1) a reiteration of the core 
recommendations, and 2) proposed revisions for the upcoming season. The following language
was proposed for a vote during this session:
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Reiteration of Core Recommendations
Annual influenza vaccination is recommended for all persons 6 months of age and older:
 A licensed, age-appropriate influenza vaccine should be used
 Recommendations for different vaccine types and specific populations discussed 
in the ACIP statement
Use of LAIV for Children 2 Through 8 Years of Age Current Language (2014-2015)
 When immediately available, LAIV should be used for healthy children aged 2 through 8 
years who have no contraindications or precautions.
Proposed revision (2015-2016)
 For healthy children aged 2 through 8 years who have no contraindications or
precautions, either LAIV or IIV is an appropriate option.  No preference is expressed for
LAIV or IIV for any person aged 2 through 49 years for whom either vaccine is
appropriate.
LAIV Recommendations (Proposed)—1 
 All persons aged ≥6 months should receive influenza vaccine annually. Influenza 
vaccination should not be delayed to procure a specific vaccine preparation if an
appropriate one is already available.
 (Proposed revision) For healthy children aged 2 through 8 years who have no 
contraindications or precautions, either LAIV or IIV is an appropriate option. No 
preference is expressed for LAIV or IIV for any person aged 2 through 49 years for
whom either vaccine is appropriate. An age-appropriate formulation of vaccine should be 
used.
LAIV Should Not Be Used for the Following Persons (Proposed)—2
 Persons aged <2 years or >49 years
 Children aged 2 through 17 years who are receiving aspirin or aspirin-containing
products
 Persons who have experienced severe allergic reactions to the vaccine or any of
its components, or to a previous dose of any influenza vaccine
 Pregnant women
 Immunosuppressed persons
 Persons with a history of egg allergy
 Children aged 2 through 4 years who have asthma or who have had a wheezing
episode noted in the medical record within the past 12 months, or for whom
parents report that a health care provider stated that they had wheezing or
asthma within the last 12 months
 Persons who have taken influenza antiviral medications within the previous 48 
hours
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LAIV Recommendations (Proposed)—3
In addition to the groups for whom LAIV is not recommended above, the “Warnings and 
Precautions” section of the LAIV package insert indicates that persons of any age with 
asthma might be at increased risk for wheezing after administration of LAIV, and notes that 
the safety of LAIV in persons with other underlying medical conditions that might predispose
them to complications after wild-type influenza infection (e.g., chronic pulmonary, 
cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or 
metabolic disorders [including diabetes mellitus]) has not been established. These 
conditions, in addition to asthma in persons aged ≥5 years, should be considered 
precautions for the use of LAIV. 
LAIV Recommendations (Proposed)—4
 Persons who care for severely immunosuppressed persons who require a protective 
environment should not receive LAIV, or should avoid contact with such persons for 7 days
after receipt, given the theoretical risk for transmission of the live attenuated vaccine virus.
Vote:  Recommendations 2015-2016 Influenza Season
Dr. Bocchini made a motion to approve the recommendations for the 2015-2016 influenza 
season. Dr. Bennett seconded the motion. The motion carried with 14 affirmative votes, 0
negative votes, and 1 abstention. The disposition of the vote was as follows:
14 Favored: Bennett, Bocchini, Campos-Outcalt, Harriman, Harrison, Karron, Kempe, 
Pellegrini, Romero, Reingold, Riley, Rubin, Temte, and Vazquez 
Dr. Temte pointed out that despite the fact that ACIP made a strong recommendation in June
2014 using the GRADE process with moderate evidence, ACIP can change as evidence 
changes. He saw this as the real power of both transparency and having a formal process by
which ACIP considers all of the evidence and makes changes as appropriate.
Human Papillomavirus (HPV) Vaccines 
Introduction
Joseph A. Bocchini, Jr, MD
Chair, ACIP HPV Vaccine Working Group
Dr. Bocchini added his thanks to Dr. Pickering for his many years of leadership and his
accomplishments as the ACIP Secretary. Due to the time constraints, the presentations for the
HPV session were shortened to provide the members with the essential information that would 
lead to a vote.
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As a reminder, the 9-valent HPV (9vHPV) vaccine was licensed by the FDA on December 10,
2014 for females 9 through 26 years of age and males 9 through 15 years of age. Trials were 
conducted with a 3-dose schedule.  This is an L1 VLP vaccine similar to quadrivalent HPV
vaccine, which targets 5 additional high risk oncogenic types (31, 33, 45, 52, and 58).  In the
US, these types are estimated to cause 14% of HPV-related cancers in women and 
approximately 5% of HPV-related cancers in males.  Males 16 through 26 years of age were not
part of the initial Biologics License Application (BLA) submitted to the FDA in 2013.  Vaccine
safety and seroconversion data from the trial in 16 through 26 year old males were presented to 
ACIP in October 2014. A supplemental BLA (sBLA) has been submitted to the FDA for this age
group.
The current recommendation for HPV vaccination in the US is for routine vaccination at age 11 
or 12 years. The vaccine series can be started as early as age 9. Vaccination is recommended
through age 26 for females and through age 21 for males who have not previously been 
vaccinated or who have not completed the series. Vaccination is recommended for
immunocompromised persons, including persons who are HIV-infected, and for men who have 
sex with men (MSM) through age 26. The current recommendation is for a 3-dose schedule
given at 0,1-2, and 6 months. The following table shows the three licensed HPV vaccines that
are currently available in the US:
In preparation for the vote during this session, a number of presentations have been provided to 
ACIP over the past year:
 Epidemiology and burden of disease due to HPV types
 February 2014
 Clinical trial data
 February 2014, June 2014, October 2014
 GRADE for 9vHPV
 October 2014
 Health economic analysis
 October 2014
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 Discussion of policy options
 October 2014
Presentations during this session will focus on 9vHPV clinical trial data, vaccine impact and 
cost-effectiveness, considerations for recommendations, and a VFC resolution.
Summary of 9vHPV Clinical Trial Data and GRADE
Emiko Petrosky, MD, MPH
EIS Officer
Epidemiology and Statistics Branch
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
During this session, Dr. Petrosky presented a brief summary of 9vHPV clinical trial data, a 
review of GRADE for 9vHPV, and considerations for a 9vHPV recommendation.  Listed in the
following table are the 9-valent vaccine studies, which have all been previously presented to the 
ACIP:
As a reminder, protocol 001 is the pivotal efficacy study that compared the 9-valent vaccine to
the quadrivalent vaccine in adult females. There were also immunobridging studies and 
concomitant use studies, and one study assessing the 9-valent vaccine in prior quadrivalent
vaccine recipients.  Dr. Petrosky presented only the results from Protocol 001, as this was the 
pivotal efficacy study, and summarized the results and safety findings from the other studies.
In Protocol 001, for the 5 additional types, the 9-valent vaccine demonstrated greater than 96%
efficacy in preventing high grade cervical, vulvar, and vaginal disease, and 6-month persistent
infection.  For outcomes due to the 4 original types, the incidence of disease in either vaccine 
group was very low, and the 9-valent vaccine demonstrated comparable protection in preventing
high grade cervical disease and anogenital warts. Both of the 9-valent and quadrivalent
vaccines induced greater than 99% seroconversion for the 4 original types, and the geometric
mean titers in the 9-valent vaccine group were non-inferior to the quadrivalent vaccine group.
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In summary, the 9-valent vaccine trial demonstrated close to 97% protection against outcomes
due to the 5 additional types and similar protection against disease due to the 4 original types.
There was very little incidence of disease in either the 9-valent or quadrivalent vaccine groups.
The 9-valent vaccine demonstrated non-inferior immunogenicity compared to the quadrivalent
vaccine for the 4 original types. Although the data were not shown during this session, the 
vaccine also demonstrated non-inferior immunogenicity for all 9 HPV vaccine types in 
adolescent females and males compared to adult females, and in adult males compared to adult
females—supporting the bridging of efficacy findings in adult females to these other groups.
The concomitant use studies demonstrated no impact on immunogenicity and safety when the 
9-valent vaccine was administered concomitantly with meningococcal vaccine (Menactra®),
Tdap vaccine (Adacel®), and Tdap-IPV vaccine (Repevax®).
Regarding safety, the 9-valent vaccine was generally well-tolerated in over 15,000 recipients
and had an AE profile similar to the quadrivalent vaccine across age, gender, race, and
ethnicity, with the exception of a higher frequency of injection-site swelling and erythema in 
females of all age groups. Males had a lower frequency of adverse events compared to
females, which is similar to what was observed in the quadrivalent vaccine program.
As a reminder, GRADE for the 9-valent vaccine was presented to the ACIP in October 2014.
The 9-valent vaccine policy questions developed by the workgroup were:
 Should the 9-valent vaccine be recommended routinely for 11 or 12 year olds?
 Should the 9-valent vaccine be recommended for females aged 13 through 26 years and
males aged 13 through 21 years who have not been previously vaccinated? (also referred to 
as catch-up vaccination)
The WG gave the overall evidence type for routine vaccination in females a ranking of 2,
indicating that the data reflected a moderate level of evidence. The WG also gave the overall
evidence for catch-up vaccination in females a ranking of 2. The following are the summary
tables for routine and catch-up 9-valent vaccination in females:
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The WG gave the overall evidence type for routine and catch-up vaccination in males a ranking
of 3, indicating a low level of evidence. The following are the summary tables for routine and
catch-up 9-valent vaccination in males.
With regard to the considerations for formulating 9-valent vaccine recommendation, the data for
the 9-valent vaccine are from randomized trials and immunobridging studies, and the WG gave 
an overall evidence type of 2 for females and 3 for males. The WG felt that the benefits of 9­
valent vaccination outweigh the harms and placed a high value on the prevention of outcomes
due to the 9 HPV vaccine types. The 9-valent vaccine is expected to be cost-saving compared




National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Dr. Chesson presented summaries of three models of 9vHPV in US, as well as the impact and 
cost-effectiveness of 9vHPV vaccination versus 4vHPV vaccination. The three US models of
9vHPV are as follows:
 US HPV-ADVISE model (Brisson et al.)
Based on published, 18-type Canadian model
 Merck Model (Weiss, Pillsbury, Dasbach)
Based on published 4vHPV model
 Simplified Model (Chesson et al.)
Based on published 4vHPV model
During the October 2014 ACIP meeting, there was a presentation of the US HPV-ADVISE 
model based on a published 18-HPV type Canadian model, which has been fitted to US data.
The Merck Model and the Simplified Model are based on former models that have been 
expanded to include the additional types of the 9-valent vaccine. All three of the 9vHPV models
are dynamic, meaning that herd effects were included in the results.  A wide range of health 
outcomes were also included:  Cervical pre-cancers and cancer; other HPV-associated cancers
47 
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(e.g., anal, vaginal, vulvar, penile, oropharyngeal); genital warts; and recurrent respiratory
papillomatosis (RRP), with the exception that the HPV-ADVISE model does not include RRP.
In the interest of time, Dr. Chesson did not discuss all of these characteristics.  In terms of the
degree of complexity and comprehensiveness, the HPV-ADVISE Model ranks the highest. The
Simplified Model ranks the lowest, and the Merck Model falls in between the two.  All of the 
models assumed high efficacy for the 9vHPV and 4vHPV vaccines, a lifetime of protection, and 
the same cost assumptions (e.g., 9vHPV was assumed to cost $13 more per dose than the
4vHPV vaccine).
Based on data from Jemal and Saraiya, Dr. Brisson’s October 2014 ACIP presentation 
regarding the potential for additional cancer prevention in the US, the greatest gain from the
9vHPV vaccine is in terms of cervical cancer prevention [Jemal JNCI 2013; Saraiya, JNCI
(under review)].  Regarding the estimated effectiveness of the 4vHPV and 9vHPV vaccines in a 
scenario in which no cross-protection is assumed for vaccine administered to boys and girls,
there is a 65% reduction in cervical cancer in the long-term with the 4vHPV vaccine. If both
sexes were switched to 9vHPV vaccine, there would be an additional 14 percentage point
decrease in cervical cancer. If cross-protection for the 4vHPV vaccine is assumed, the 4vHPV
vaccine would have a greater impact and the marginal impact of the 9vHPV vaccine would be 
reduced. In terms of sex-specific 9vHPV vaccine strategies and the outcomes of cervical 
intraepithelial neoplasia (CIN) 2/3 and cervical cancer, the majority of the benefit is achieved 
through switching females to the 9vHPV vaccine.
Regarding the cost-effectiveness results from the HPV-ADVISE model, under the scenario of no
cross-protection for 4vHPV vaccine, 9vHPV vaccination for females and 4vHPV vaccine for
males compared to a strategy of 4vHPV vaccine for both sexes shows the incremental cost-
effectiveness of switching females from the 4vHPV vaccine to the 9vHPV vaccine and indicates
that this is cost-saving.  This suggests that the additional costs of the 9vHPV vaccine are offset
by the averted medical costs due to the additional benefits of the 9vHPV vaccine. The 
comparison of the strategy of  9vHPV vaccine for both sexes compared to the strategy of
9vHPV vaccine for females and 4vHPV vaccine for males shows that the incremental cost-
effectiveness of switching males from 4vHPV to 9vHPV vaccine would be $31,000 per quality
adjusted life year (QALY). In a scenario in which both sexes are switched from 4vHPV to 
9vHPV vaccine, the cost per QALY would be less than zero or cost-saving. The WG believes
that this is the most applicable scenario to the current decision facing ACIP, given that sex-
specific vaccine strategies are not likely to be a viable policy alternative in the US.
In terms of the bottom line, all three models suggest that a scenario in which no cross-protection
is assumed for the 4vHPV, switching from 4vHPV to 9vHPV likely would be cost-saving.  When
cross-protection is assumed for the 4vHPV vaccine, the results are similar across all models in
that the cost per QALY gained by 9vHPV vaccination would be low. This strategy remains cost-
saving in the HPV-ADVISE Model, and is only $8,000 per QALY in the Simplified Model. The 
results were consistent in a range of sensitivity analyses when 9vHPV vaccine was compared to
4vHPV vaccine for both sexes. The mean cost per QALY gained was less than $0 in most
scenarios examined. The two exceptions were when 4vHPV cross-protection was assumed, in 
which the cost per QALY was $4,600 in the high coverage scenario and $6,600 in the low health 
care cost scenario. With respect to the uncertainty intervals generated in the analyses, the cost
per QALY gained by the 9vHPV vaccine remained less than $10,000 when assuming no cross-
protection for the 4vHPV vaccine and less than $25,000 when assuming cross protection for the
4vHPV vaccine.
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In conclusion, the current 4vHPV program is expected to reduce HPV-related diseases
substantially in the US. Switching to a 9vHPV program is expected to further reduce pre­
cancerous lesions and cervical cancer. The HPV-ADVISE model suggested additional
reductions of 19% and 14% reduction in CIN2/3 and cervical cancer, respectively, with perhaps
more modest reductions in the other HPV-associated cancers. Providing 9vHPV vaccine for
girls provides the great majority of benefits of providing 9vHPV vaccination to both sexes.  
Primary 9vHPV vaccine for both sexes is likely cost-saving compared to 4vHPV vaccine for both
sexes.  Again, these results are consistent not only across the three models, but also within 
each model as the assumptions are varied. The cost per QALY gained by 9vHPV did not
exceed $25,000 in the sensitivity analyses, and was less than zero in most of the scenarios
examined.  Analyses of additional 9vHPV for prior 3-dose 4vHPV vaccine recipients is
underway; however, preliminary results are highly variable because of the incremental health
benefit in terms of the gain per person vaccinated is quite small.
Proposed Recommendations for Use of 9vHPV Vaccine
Lauri Markowitz, MD
HPV Vaccine Working Group
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Dr. Markowitz mentioned with regard to Dr. Chesson’s last point, that the provision of 9vHPV
vaccine to individuals who have already received 4vHPV vaccine is an ongoing consideration 
for which additional modeling is being done. Given the time constraints due to the short ACIP 
meeting, it was not possible to address this issue adequately during this session.
For the 9vHPV vaccine recommendations, the plan is to publish an MMWR Policy Note. These
are shorter than a full ACIP statement.  There will be a link to the GRADE tables on the ACIP 





 Vaccine pregnancy registry
 Future policy issues
For each, she briefly reviewed some considerations discussed by the WG and then presented
the draft wording to be included in the Policy Note.
For routine recommendations and age groups, the WG proposed the same age groups as in the 
current recommendations. 9vHPV use in males older than age 15 years would be off-label at
present and was discussed previously with ACIP.  Immunogenicity data in males 16 through 26
years were presented to ACIP in October 2014, included in GRADE, and were submitted to the 
FDA.  Compared with 4vHPV, 9vHPV would provide little additional benefit for males.  However,
programmatic issues were considered for male recommendations, including the low likelihood 
that providers would stock two different HPV vaccines and the fact that there eventually will be a 
transition from 4vHPV to 9vHPV vaccine.
49 







   
  
  
   
    
 
  
   
      






    
   
  
  
     
   
  
 
   
    
     
     
    
    
     
     




       





Advisory Committee on Immunization Practices (ACIP) Summary Report February 26, 2015
The proposed routine recommendation follows, with new wording underlined:
“ACIP recommends routine HPV vaccination at age 11 or 12 years. The vaccination 
series can be started beginning at age 9 years. Vaccination is also recommended for
females aged 13 through 26 years and for males aged 13 through 21 years who have 
not been vaccinated previously or who have not completed the 3-dose series. Males
aged 22 through 26 years may be vaccinated.* Vaccination of females is recommended 
with 2vHPV, 4vHPV (as long as this formulation is available), or 9vHPV. Vaccination of
males is recommended with 4vHPV (as long as this formulation is available) or 9vHPV.”
*Recommendation for men who have sex with men and for immunocompromised 
persons (including those with HIV infection) are also included in “Special Populations”:
“Vaccination is also recommended for men who have sex with men or for
immunocompromised persons (including those with HIV infection) aged 22 through 26
years, if not vaccinated previously.”
“2vHPV, 4vHPV and 9vHPV all protect against HPV 16 and 18, types that cause about
66% of cervical cancers and the majority of other HPV-attributable cancers in the United 
States. 9vHPV targets five additional cancer causing types, which account for about
15% of cervical cancers. 4vHPV and 9vHPV also protect against HPV 6 and 11, types
that cause genital warts.”
There will be a link to the GRADE tables in the recommendations. The proposed wording does
not specifically state a preference for any vaccine, but outlines the differences between the
vaccines and what they can protect against.
The current wording in the section on administration addressing intervals is, “The second dose
should be administered 1–2 months after the first dose and the third dose 6 months after the
first dose.” Of note is that studies of 4vHPV and 2vHPV vaccine show that longer intervals
between doses do not result in lower antibody titers, and some studies found higher titers after
longer intervals.  The WG discussed the value of mentioning flexibility in schedules. The pros 
and cons of this were discussed.  Some WG members felt this was important to mention.  
Others were concerned about possible confusion for vaccination providers. The compromise 
was to allow flexibility by changing some of the wording.  Also of note is that the intervals on the
schedule will remain the same at 0, 1-2, and 6 months. The proposed wording for
administration follows:
“2vHPV, 4vHPV and 9vHPV are each administered in a 3-dose schedule. The second 
dose should be is administered at least 1 to 2 months after the first dose, and the third 
dose at least 6 months after the first dose. If the vaccine schedule is interrupted, for 
either HPV4 or HPV2, the vaccination series does not need to be restarted.”
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There have been no studies of the interchangeability of HPV vaccines.  However, there are 
some data on 9vHPV vaccine after three doses of 4vHPV vaccine from a study conducted as
part of the 9vHPV vaccine clinical program. The WG discussed programmatic issues related to 
transition to the 9vHPV vaccine for consideration of wording.  Again, the cross-outs and
underlines show items to remove and add:
“ACIP recommends that the HPV vaccination series for females be completed with the
same HPV vaccine product, whenever possible. However, If vaccination providers do not
know or do not have available the HPV vaccine product previously administered, or are
in settings transitioning to 9vHPV, for protection against HPV 16 and 18 either any HPV 
vaccine product may be used to continue or complete the series for females; to provide 
protection against HPV 16 and HPV 18.  Only HPV4 is licensed for use in males 4vHPV 
or 9vHPV may be used to continue or complete the series for males.”
No changes were proposed to the recommendations for vaccination during pregnancy.  This
section is being updated to reflect new information on vaccine in pregnancy registries. A 
pregnancy registry has been established for 9vHPV. Also of note is that the bivalent vaccine 
pregnancy registry was closed earlier this month with concurrence from FDA. Wording will be
added about the 9vHPV vaccine and a note will be made that the quadrivalent and bivalent
vaccine registries have been closed. The proposed pregnancy recommendation follows:
“Patients and health care providers can report an exposure to HPV vaccine during
pregnancy to Vaccine Adverse Event Reporting System (VAERS).  A new registry has
been established for 9vHPV. Pregnancy registries for 4vHPV and 2vHPV have been 
closed with concurrence from FDA. Exposure during pregnancy should be reported to 
the respective manufacturer.”
The last issue for which there was discussion in the WG was Future Policy Issues, a short
section proposed at the end of the Policy Note.  The discussion centered on what should be 
included in the policy note specifically related to the ongoing trial of a 2-dose schedule with 9­
valent HPV vaccine.  Some WG members were concerned about confusion for providers, which 
could lead to delay in vaccination. However, the WG came to a compromise for the proposed
wording for this section which follows:
“A clinical trial is ongoing to assess alternate dosing schedules of 9vHPV. ACIP will
formally review the results as data become available. HPV vaccination should not be
delayed pending availability of 9vHPV or of future clinical trial data.”
Though not under consideration during this session, the WG is discussing 9vHPV vaccine for
persons who previously completed an HPV vaccination series.  It is important to note that the
manufacturer did not seek an indication for 9vHPV vaccine in persons who previously
completed an HPV vaccination series.  However, a study was conducted that evaluated 9vHPV
vaccine in prior 4vHPV vaccinees (Protocol 006) and the data are included in the label.  Due to 
the time constraints of this session, these data will be presented during the June 2015 ACIP
meeting.
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Discussion Points
Ms. Pellegrini thanked the WG for the revised language on administration.  She thought it would 
be very helpful in parent education to be able to say that the series does not have to be 
completed within a very restrictive timeframe for teens.  Regarding interchangeability, it seemed
like there was an implicit recommendation not to use bivalent vaccine and that 4vHPV or 9vHPV
vaccine should be used to complete a series.
Dr. Markowitz replied that for females, the goal was to convey that any vaccine could be used to 
continue or complete a series.  Since only one vaccine was approved and recommended for
males last time, there was not a separate statement for males. There are now separate 
statements.
Ms. Pellegrini indicated that she would communicate further with the WG offline.
Dr. Harriman said the same language indicated to him that if a provider has 4vHPV vaccine and 
that is what someone began with, it would be preferred.
Dr. Markowitz indicated that they tried to soften the language by removing the first sentence,
because it suggested that ACIP recommends that the vaccination series for females should be 
completed with the same product whenever possible. They wanted to liberalize this,
acknowledging what would eventually occur with the transition.
Dr. Harriman pointed out that if there was not a preference to use 4vHPV if that was already
started, it seemed like the language used for males could be used.
Dr. Markowitz said the WG tried to make the language the same for males and females. The 
only difference is the vaccines that are recommended for males and females.  She asked 
whether part of the language should address vaccine providers who do not know the previous
vaccines given, do not have 4vHPV vaccine available, or are transitioning to 9vHPV.
Dr. Harrison suggested that it read, “If the vaccine series has already been started, either
vaccine can be used to complete the series” rather than “if you do not have 4vHPV.”
Dr. Markowitz emphasized that the sentence was meant to apply to both males and females,
and was not meant to read that way just for females.
Dr. Bennett pointed out that a provider could still be giving the bivalent vaccine for females;
whereas, for males that would not be indicated.
Dr. Temte requested a reminder about the current percentage of 4vHPV vaccine being used in 
the US.
Dr. Markowitz replied that probably over 98% of vaccine being used is 4vHPV, so the
recommendation is geared toward people who are giving quadrivalent vaccine.
Dr. Temte noted that in essence, the WG was being very inclusive but was also acknowledging 
reality, which he thought was nicely conveyed.
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Dr. Sawyer pointed out that the statement that some studies have demonstrated higher titers
with longer intervals will invite providers to ask how much longer.  He asked how this would be 
addressed in the Policy Note.
Dr. Markowitz replied that some clarification could be added about this. There is limited room in 
the Policy Note, so it does not contain that level of detail.  Perhaps some language could be
added.
Dr. Sawyer thought that language should be added to put a boundary around the intervals in 
terms of what the data show.  Then providers can decide.
Dr. Lett asked whether any language would appear in the Policy Note about the data pertaining
to revaccination even though this information was not presented during this session.
Dr. Markowitz thought they could ask the ACIP members how they felt about this. The ACIP
has not been able to discuss this, so they could be silent on that matter or could indicate some 
place in the Policy Note that this will be discussed in the future.
Dr. Schuchat indicated that this is an issue that ACIP has not been able to deliberate, so there 
are other ways that CDC can make some factual information available to clinicians pending
ACIP deliberating on what they would like to say about the matter.
Dr. Temte stressed that because this will be addressed during the June 2015 meeting, he was
not uncomfortable having a four-month window, especially in terms of an off-label use for a new
product with which people are just becoming familiar .
Dr. Harrison requested clarity about whether there would be a vote in June or just an informal
session about those previously vaccinated with quadrivalent vaccine.
Dr. Markowitz assumed they would be anticipating a vote on the wording if ACIP wanted that
included in a Policy Note.
Dr. Harrison wondered whether consideration should be given to an informational session 
before the next meeting regarding this and the MenB issue. In the past, the members have had 
some difficulty being presented with a recommendation that addresses information that is not
straightforward, or making decision on the spot and trying to take a vote during the same 
meeting.
Dr. Schuchat indicated that it would not be possible to convene an informational session prior to 
the June meeting.
Dr. Markowitz added that information could be provided to members as background materials
before the June meeting, which would probably offer enough information for the members to be 
able to address this.
Dr. Middleman (SAHM) asked whether it might be helpful to add a statement about efficacy
being known only if the series is completed in order to ensure that completion is the end game.
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Dr. Markowitz suggested that one other way that might avoid confusion would be to eliminate
the sentence entirely which states that “some studies have found” and just say that “the second 
dose should be administered at least one to two months later, and the third dose at least six
months later.” Others agreed that this would be a good idea.  Dr. Markowitz pointed out that
this does not differ from the current recommendations stating that if the vaccination schedule is
interrupted, it does not need to be restarted. This was just to clarify by highlighting the intervals.
Vote:  HPV Package
Dr. Rubin made a motion to approve the package of HPV vaccine recommendations, with 
deletion of the sentence pertaining to antibody levels being higher with longer intervals between 
doses.  Dr. Vazquez seconded the motion. The motion carried with 14 affirmative votes, 0
negative votes, and 1 abstention. The disposition of the vote was as follows:
14 Favored: Bennett, Belongia, Bocchini, Campos-Outcalt, Harriman, Harrison, Karron, 
Kempe, Pellegrini, Romero, Riley, Rubin, Temte, and Vazquez
0 Opposed: N/A
1 Abstained: Reingold
Dr. Fryhofer (ACP) acknowledged the time constraints of the current meeting, but emphasized 
that the question regarding revaccination with 9vHPV of patients who received 4vHPV is raised 
by many practitioners.  ACP looks forward to guidance from ACIP and in getting the word out
about what should be done.
Dr. Neuzil (IDSA) thought one of the most common questions following publication of the new
recommendations would relate to the timeline of the availability of 9vHPV vaccine. Therefore, it
would be helpful if someone could comment on that before the end of the session.
Julie McCafferty (Merck) indicated that Merck has 9vHPV vaccine currently available, as well as
a continued supply of Gardasil®. They are also waiting for greater commercial coverage from an
insurance perspective for 9vHPV vaccine to be more broadly available in the US.
Vaccines for Children
Dr. Jeanne M. Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Santoli explained that the purpose of this presentation was to update the resolution to
include use of a 9vHPV vaccine that was recently licensed for use and to clarify the schedule 
and timing of vaccine intervals. The recommendations proposed follow.
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Eligible Groups:











Not eligible Eligible Eligible
Recommended Schedule and Interval:
 ACIP recommends routine HPV vaccination at age 11 or 12 years. Eligible females and
males as young as 9 years old may be vaccinated.  Vaccination is recommended for
females and males 13 through 18 years of age who have not been previously vaccinated or
who have not completed the full series.
 HPV2, HPV4 and HPV9 are each administered in a 3-dose schedule. The second dose is
administered at least 1 to 2 months after the first dose and the third dose at least 6 months
after the first dose.
 If vaccination providers do not know, or do not have available the HPV vaccine product
previously administered, or are in clinical settings transitioning to HPV9, for protection 
against HPV 16 and 18, any available HPV vaccine product may be used to continue or
complete the series for females; HPV9 or HPV4 may be used to continue or complete the 
series for males.
 If the vaccine schedule is interrupted, the vaccine series does not need to be restarted. The 
first and second doses should be separated by an interval of least four weeks.  The second 
and third doses should be separated by an interval of at least 12 weeks, with a minimum
interval of 24 weeks between the first and third doses.
Recommended Dosage and Contraindications/Precautions:
 Recommended dosage
Refer to product package inserts.
 Contraindications and Precautions




Statement Regarding Update Based on Published Documents
[If an ACIP recommendation regarding HPV vaccination is published within 12 months following
this resolution, the relevant language above (except in the eligible groups sections) will be 
replaced with the language in the recommendation and incorporated by reference to the 
publication URL.]
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Discussion Points
Dr. Harriman suggested that it would be valuable to use the exact same language from the
Policy Note in the VFC recommendation in terms of weeks and months.
Dr. Markowitz noted that some of the minimal intervals historically have been in weeks, which 
relates to registries and how they are used. The minimal intervals do mirror each other, which 
she did not show because these have not changed.
Dr. Temte pointed out that forecasting for systems needs a specific numbers of days, which 
cannot be done with months because the number of days in a month can vary.  As long as it is
consistent with other VFC resolutions, he thought they could let it stand.
Dr. Harriman emphasized that it would be nice for the language to be harmonized throughout.
Perhaps it needs to go in the other direction—the Policy Note should mirror the VFC.
Dr. Schuchat indicated that the readers of the VFC are not the same. Obviously, there is
strengthening of the quality when there is harmonization, so they will take this back.
Vote: VFC for HPV
Dr. Kempe made a motion to approve the VFC recommendations for HPV vaccination.  Dr.
Romero seconded the motion. The motion carried with 14 affirmative votes, 0 negative votes,
and 1 abstention. The disposition of the vote was as follows:
14 Favored: Bennett, Belongia, Bocchini, Campos-Outcalt, Harriman, Harrison, Karron, 
Kempe, Pellegrini, Romero, Riley, Rubin, Temte, and Vazquez 
0 Opposed: N/A
1 Abstained: Reingold
Yellow Fever Vaccine 
Introduction
Joseph A. Bocchini, Jr, MD
ACIP, Workgroup Chair
Japanese Encephalitis (JE) and YF (YF) Vaccines WG
Professor and Chairman, Department of Pediatrics
Louisiana State University Health Sciences Center
Dr. Bocchini indicated that during this session, the Japanese Encephalitis (JE) and Yellow Fever
(YF) Vaccines WG would present follow-up information related to YF vaccine in anticipation of
an ACIP vote.  He thanked the members of the WG for their participation, especially Dr. Erin
Staples for her work as the CDC lead for this WG.
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As a reminder, WHO’s Strategic Advisory Group of Experts (SAGE) concluded in April 2013 that 
a single dose of YF vaccine is sufficient to confer lifelong protection and that booster doses
were no longer needed. Additional data, however, were indicated by the WHO for identifying
specific risk groups who might benefit from a second dose or a booster dose. Since 1965,
International Health Regulations (IHRs) have allowed countries to require a YF vaccine dose
within the past 10 years for entry. In June 2014, the WHO’s World Health Assembly (WHA)
adopted an amendment to the IHR that extends YF vaccine protection to the life of the person 
vaccinated.  That change will take effect in June 2016, so there will no longer be a requirement
for countries to maintain that 10-year interval.
Because of those changes, the JE Vaccine WG was re-formed to include YF vaccine in October
2013. The WG met multiple times to discuss the booster doses.  ACIP has heard three 
previous presentations on this topic, including a presentation of GRADE.  In June 2014, the WG
presented the initial set of recommendations. Subsequently, feedback was received from ACIP
and the WG continued to meet to address the issues raised by the members. During the June
meeting, there was general support to remove the booster dose requirement, but questions
were raised about groups for whom additional doses would be considered. There was
discussion regarding the immune response in children, the interval between doses in certain 
groups, and what constitutes high-risk settings for exposure to YF.
With respect to the issue related to children, the WG worked with AAP’s COID. A presentation 
was made during COID’s November 2014 meeting.  An updated analysis on immune response 
for children and whether children’s immune response to YF vaccine differed from adults were 
discussed. The WG also discussed the time interval for additional doses in pregnant women,
hematopoietic stem cell transplant recipients, HIV-infected individuals, and high-risk settings for
exposure to wild-type YF virus.
During this session, Dr. Staples presented a summary of the GRADE review, considerations for 
special populations, and proposed recommendations for consideration and a vote by ACIP.
GRADE Summary for YF Booster Doses, Consideration of
Booster Doses in Specific Populations, and Proposed Recommendations
J. Erin Staples, MD, PhD
Arboviral Diseases Branch
Division of Vector-Borne Diseases
Centers for Disease Control and Prevention
Dr. Staples reminded everyone that the primary policy question the WG studied for GRADE
was, “Should booster doses of YF vaccine every 10 years continue to be recommended for
healthy travelers and laboratory workers?” The intervention would be to remove the current
recommendation for booster doses.  The current option is to continue the current
recommendation for booster doses of YF vaccine.
In terms of the outcome measures the WG assessed for YF vaccine booster doses in the 
GRADE evaluation, the benefits included vaccine efficacy, seroprotection, vaccine 
effectiveness, and seropositivity.  However, there are no data on vaccine efficacy or
seroprotection. The three harms the WG considered to be critical included SAEs, viscerotropic
disease, and neurologic disease.  Dr. Staples reviewed the main findings for each critical
outcome.
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Vaccine effectiveness was defined as a lack of vaccine failures.  Among over 540 million doses
of YF vaccine administered, 18 vaccine failures have been identified. Only 2 (11%) of the 18
vaccine failures occurred more than 10 years from the last dose of vaccine at 20 and 27 years.
Regarding seropositivity data at ≥10 years following YF vaccination, there were 13 
observational studies with immunogenicity data for 1137 persons. The estimate of seropositivity
is 92% (95%CI 85%-96%) using a random effects model. There were three observational
studies with immunogenicity data for 164 people ≥20 years post-vaccination. The estimate for
seropositivity for this group is 80% (95% CI 74%-86%) random effects model.
Moving to the harms, there were nine observational studies that had data on 333 million doses
of the vaccine distributed. There were 1255 subjects who reported SAEs following vaccination.
Of the 201 subjects for whom the dose type was known, 7% occurred following a booster dose 
of YF vaccine. The data were similar for YF vaccine-associated viscerotropic and neurologic
disease.
As a reminder, the initial evidence types used for GRADE are as follows (with 1 being the 
highest level of confidence in the estimated effects on the outcomes and 4 being the lowest):
1 Randomized control trials (RCTs) or overwhelming evidence from observational
studies
2 RCTs with important limitations or exceptionally strong evidence from observational
studies
3 Observational studies or RCTs with notable limitations
4 Clinical experience, observational studies with important limitations, or RCTs with
several major limitations
The quality of evidence for each of the five critical outcomes assessed for YF vaccine booster
doses was 4, given that only observational studies were included.  All of the observational
studies had important limitations specifically related to bias and indirectness. The overall quality
of evidence was 4.
An additional policy question was created to address persons who were considered by the WG
not to belong to healthy travelers and laboratory workers, which was “Should booster doses of
YF vaccine every 10 years continue to be recommended for travelers and laboratory workers
who had a precaution to vaccination that might have negatively impacted their immune 
response to their primary dose of YF vaccine (e.g., pregnancy, asymptomatic HIV infection, or
age 6 through 8 months)?
Two observational studies provided immunogenicity data for pregnant women following YF
vaccination.  In the first study, 39% (32/83) of pregnant women vaccinated during their third
trimester seroconverted.  This is in comparison to 94% (89/95) of the general population who 
received the vaccine at the same time in Nigeria as part of an outbreak response. In a second
study conducted in Brazil, 98% (425/433) of pregnant women vaccinated primarily during their
first trimester seroconverted and developed YF virus-specific antibodies. From these two 
studies, the conclusion can be drawn that the proportion of pregnant women who develop
antibody titers following YF vaccination is variable, but data indicate a lack of initial 
seroconversion for some pregnant women. Given this, the WG suggests revaccinating women 
who receive their initial dose of YF vaccine while pregnant one time prior to their next at-risk
travel.
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There are no immunogenicity data for YF vaccine in hematopoietic stem cell (HSCT) recipients.
However, the data suggests that most recipients become seronegative to live viral vaccine 
antigens post-transplantation. The Infectious Disease Society of America (IDSA) guidelines
currently recommend re-administering live viral vaccines, specifically measles, mumps, rubella
(MMR) and varicella vaccines post-transplant when the recipient is no longer
immunosuppressed.  Given this, the WG suggested revaccinating HSCT recipients one time
prior to their next at-risk travel as long as they are immunocompetent.
Three studies compared the immunogenicity of YF vaccine in HIV-infected persons to
uninfected persons.  In the first study, 17% (3/18) of HIV-infected children had YF virus-specific
antibodies on average 10 months post-vaccination. This is in comparison to 74% (42/57) in age 
and nutritionally matched children. In the second study, 83% (65/78) of HIV-infected travelers
had YF virus-specific antibodies one year post-vaccination in comparison to 97% (64/66) of
uninfected controls. In the third study, 77% (54/70) of HIV-infected travelers had YF virus-
specific antibodies at 1 to 10 years post-vaccination in comparison to 88% (81/92) of uninfected 
controls. To summarize, the data indicate that HIV-infected persons are less likely to have
sustained YF virus-specific antibody titers following vaccination.  Given this, the WG suggested
continuing doses of YF vaccine every 10 years for persons who received YF vaccine while 
infected with HIV.
A specific area of discussion following the June 2014 ACIP meeting was young children.  There 
were 12 studies with immunogenicity data on 4675 children aged 4 months to 10 years in 
endemic areas at least 1 to 2 months post-vaccination. The estimated seroconversion rate is
93% (88%-96%) using a random effects model. Differences in seroconversion rates were 
compared among different pediatric age groups. Because the studies often aggregated their
results by age, there were two age groups that could be readily explored. The seroconversion 
rates for children aged ≥9 months compared to children aged <9 months were 92% (95% CI
86%-96%) and 95% (95% CI 91%-98%), respectfully. The seroconversion rates for children 
aged ≥12 months compared to children aged <12 months were 89% (95% CI 78%-96%) and
93% (95% CI 87%-97%), respectfully. To summarize the pediatric data and note other
considerations, the estimated pediatric seroconversion rate was 93% (95% CI 88-96%).  The
unadjusted seroconversion rate for adults at the same time point is 98% percent for all
populations and 97% for endemic populations. As a reminder, the pediatric data were only from
endemic areas. Based on available data, there are no clear age differences in seroconversion 
rates.  When these data were presented and discussed with the AAP’s COID, they concluded 
that young children were not immunologically different from adults in their response to YF
vaccine.
The WG also considered persons thought to be at higher risk for YF virus exposure based on
season, location, activities, and duration of their exposure. The situations in which persons are
considered to be at risk for YF virus exposure include West Africa during peak transmission
season, where the disease risk is estimated to be approximately 10 times higher than South
America; areas with ongoing outbreaks; laboratory settings with regular exposure to wild-type 
YF virus; and travel for long periods of time (e.g., months to years).
To summarize YF vaccine booster dose data and considerations, very few vaccine failures were 
noted following YF vaccine.  Most (92%) vaccine recipients are seropositive at ≥10 years post-
vaccination.  SAEs are uncommon following booster doses of YF vaccine.  High value is placed 
on preventing a serious disease with no treatment and poor outcome.  The current statement in
the ACIP recommendations will no longer be relevant when the IHR is updated in June 2016.
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Based on the available data, the WG concluded that a single dose of YF vaccine provides long-
lasting protection in most travelers. Therefore, the WG would no longer recommend booster
doses of YF vaccine for most travelers.  YF vaccine booster doses should be recommended for
persons whose immune response to a previous dose might have been compromised.  
Consideration should be given to YF vaccine booster doses for persons in higher-risk settings
for exposure to YF virus. With this in mind, the WG proposed the following recommendations
for ACIP’s consideration and vote:
For Most Travelers
“A single dose of yellow fever vaccine provides long-lasting protection and is adequate
for most travelers.” (Recommendation category A)
Recommendations for Certain Populations
“Additional doses of yellow fever vaccine are recommended for certain travelers,
including:
 Women pregnant when they received their initial dose of yellow fever vaccine
should receive one additional dose of yellow fever vaccine prior to their next
travel that puts them at risk for yellow fever virus infection.
 Individuals who received a hematopoietic stem cell transplant after receiving a
dose of YF vaccine and who are sufficiently immunocompetent to be safely
vaccinated should be revaccinated prior to their next travel that puts them at risk
for yellow fever virus infection.
 Individuals who were HIV-infected when they received their last dose of yellow
fever vaccine should receive a dose every 10 years if they continue to be at risk
for yellow fever virus infection.
Persons being considered for additional doses of yellow fever vaccine should be 
assessed for contraindications or precautions.” (Recommendation category A)
Recommendations for High-Risk Settings
“A booster dose may be considered for travelers who received their last dose of YF 
vaccine at least 10 years previously and who will be in a higher-risk setting based on
season, location, activities, and duration of their travel. This would include travelers who 
plan to spend a prolonged period of time in endemic areas or those traveling to highly
endemic areas such as rural West Africa during peak transmission season or areas with 
ongoing outbreaks.” (Recommendation category B)
Recommendation for Laboratory Workers
“Laboratory workers who routinely handle wild-type yellow fever virus should have yellow 
fever virus-specific neutralizing antibody titers measured at least every 10 years to 
determine if they should receive additional doses of the vaccine. For laboratory workers 
who are unable to have neutralizing antibody titers measured, yellow fever vaccine 
should be given every 10 years as long as they remain at risk.” (Recommendation 
category A).  
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Discussion Points
Dr. Reingold inquired as to whether the rationale for recommending vaccination for all pregnant
women was because it is unlikely that women will know the trimester in which they were 
vaccinated.
Dr. Staples replied that the information was derived from only two studies, which is insufficient
to conclude with certainty that the third trimester is the issue. The recommendation is more 
conservative in saying that if a woman is vaccinated during pregnancy, she should receive 
another dose if possible.
Dr. Campos-Outcalt asked whether the option of antibody titers had been considered for groups
under consideration for revaccination other than laboratory workers, given that there was some
seroconversion among all of the groups, and given that AEs can occur with the vaccine.
Dr. Staples indicated that the WG did discuss antibody titers.  Currently, the only place that
performs antibody titer testing is CDC’s Fort Collins facility. This is done with a plaque
neutralization test, and the results take about four weeks.  The travel practitioners in the WG did 
not think this would be very practical from a time and logistics perspectives. CDC traditionally
does antibody testing for many of the high-risk groups of concern. That is already being done 
and could be maintained. The number of laboratory workers who handle wild-type YF virus on a 
regular basis is quite small, and they will be aware of and should be able to obtain neutralization
testing.
Ms. Pellegrini recalled that during the fall discussion regarding children, there was some
question about whether travelers who were vaccinated as children would, indeed, have lifelong 
protection.  She wondered whether the WG was able to find any data that would help clarify this.
Dr. Staples responded that the WG reviewed the pediatric data, and she showed all of the data
available for the initial seroconversion.  There is only one study available and the data do not
deal primarily with YF. Instead, the study assessed children who received YF vaccine because
they were going to receive their chimeric dengue vaccine. The children in this study were 
assessed based on age cohorts.  Given that some of them had been revaccinated, the results
are confusing and unhelpful. The AAP agreed that additional data would be beneficial, and this
is one of the studies that the WG has highlighted for future work.
Dr. William Atkinson indicated that he was posing a question on behalf of Dr. Stanley Plotkin,
who was unable to attend due to the Southern snowstorm.  Dr. Plotkin’s inquiry pertained to the 
study recently published in Vaccine showing 17% seronegative 5 to 9 years in normal
individuals.
Dr. Staples replied that she would have to review the specific data to which Dr. Plotkin was
referring, given that several YF vaccine studies had been published in Vaccine in the last six
months. The WG has also been grappling with what actually constitutes “seroprotection,” 
because different assays and different cutoffs are used to represent what would be detectable 
antibodies. Therefore, it would be difficult to comment on the results of a particular study
without seeing those types of details.
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Vote:  YF Vaccine Booster Dose
Dr. Rubin made a motion to approve the recommendations for a Yellow Fever vaccine booster
dose. Dr. Belongia seconded the motion. The motion carried with 15 affirmative votes, 0
negative votes, and 0 abstentions. The disposition of the vote was as follows:
15 Favored: Bennett, Bocchini, Belongia, Campos-Outcalt, Harriman, Harrison, Karron,




No public comments were offered during this specific session. Given that all public comments
presented during this meeting pertained to meningococcal vaccine, they are included within the 
meningococcal section of this document.
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Certification 
Upon reviewing the foregoing version of the February 26, 2015 ACIP meeting minutes, Dr.
Jonathan Temte, ACIP Chair, certified that to the best of his knowledge, they are accurate and 
complete. His original, signed certification is on file with the Management Analysis and Services
Office (MASO) of CDC.
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American Academy of Family Physicians (AAFP)
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American Academy of Pediatrics (AAP)
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American Osteopathic Association (AOA)
GROGG, Stanley E., DO, FACOP
Associate Dean/Professor of Pediatrics
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Infectious Diseases Society of America (IDSA) (alternate) 
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